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ABSTRACT
THE ROLE OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) IN FIBROSIS
ASSOCIATED WITH INTESTINAL NEUROENDOCRINE TUMORS.
Michael D. Shapiro, Mark Kidd, and Irvin M. Modlin. Section of Surgical Gastroenterology,
Department of Surgery, Yale University, School of Medicine, New Haven, CT.
Carcinoid tumors of the small bowel often present with fibrosis in the peritumoral tissues, distant
in the heart or lungs, and locally in the peritoneal cavity. The mechanism of the fibroblastic
lesions in patients with small bowel carcinoids is unclear and their timely diagnosis impossible.
There exists no test to determine the risk of fibrosis, detect its presence, or monitor its
progression once discovered. Furthermore, no current therapy protects against such fibrosis. We
have proposed that CTGF, a mediator of the profibrotic activities of TGFβ1 (a known regulator
of fibrosis) is directly involved in the genesis of ileal carcinoid-related fibrosis. The aim of this
study was to assess the potential correlation of serum and tissue CTGF with the diagnosis of
carcinoid-related fibrosis. Serum and tissue samples from patients with GI carcinoids, other GI
and extra-GI malignancies, and control patients were collected prospectively. A GI carcinoid
tissue microarray (TMA) was stained immunohistochemically with anti-CTGF, semiquantitatively measured, and analyzed for correlation with clinical fibrosis. Significantly higher
serum CTGF levels were found in patients with ileal carcinoids than in patients with gastric ECL
cell carcinoids (the latter of which are not associated with fibrosis) and control patients. Our
results demonstrated that CTGF protein is over-expressed in small bowel carcinoid tumors
associated with fibrosis and that the secreted protein is stable and detectable in patient serum.
The correlation of CTGF with TGFβ1 suggests that CTGF is a co-secreted fibrotic factor. Since
the relationship of CTGF to fibrosis is well defined, this cytokine may be involved in the genesis
of ileal carcinoid-related fibrosis. The detection of elevated levels may provide a diagnostic
opportunity to predict fibrosis and pre-empt its local and systemic complications. Furthermore,
CTGF may represent a therapeutic target for management of fibrosis-related complications in
patients with carcinoid tumors.
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INTRODUCTION

Carcinoid tumors are enigmatic, slow-growing neuroendocrine neoplasms derived
from the serotonin-producing enterochromaffin (EC) cell and are most commonly associated
with the gut and broncho-pulmonary system. The secretion of the tumor’s vasoactive
substances, particularly serotonin, can manifest systemically with paroxysmal flushing,
diarrhea, cardiac valve abnormalities, increased skin pigmentation and bronchospasm—the
1

classic hallmarks of the carcinoid syndrome . In many instances, however, they are identified
at surgery for unexplained bowel obstruction or during exploration of the small bowel in
search of a primary tumor once distant metastases have been detected.
Despite medical and therapeutic advances that have alleviated symptoms and
2

prolonged life (particularly somatostatin [SST] receptor targeted pharmacotherapy) , a
substantial subset of patients with midgut carcinoids develops mesenteric and intestinal
carcinoid fibrosis and/or carcinoid heart disease. Both of these conditions reflect a connective
3

tissue disorder whose etiology, biology and therapy are unknown . Tumor growth results in a
marked fibrogenic response with the development of peritoneal and mesenteric fibrosis (164

48%) , the management of which has become a dominant clinical issue. In contrast, gastric
carcinoids, derived from the histamine-secreting enterochromaffin-like (ECL) cell of the
stomach, are not associated with the development of fibrosis.
The mechanism of the fibroblastic lesions in small bowel carcinoid patients is unclear
and their timely diagnosis impossible unless fortuitous intestinal obstruction leads to early
surgery. As patients survive longer and are relatively symptom-free because of SST analogue
therapy, the issue of carcinoid-engendered fibrosis has emerged as the most critical and

7
4

completely unanswered question in the management of patients with these tumors . There is
no understanding of the mechanistic basis of fibrosis, no method to detect it before it causes
either bowel obstruction or cardiac valve dysfunction, and no treatment to control carcinoidrelated fibrogenesis. The development and consequences of fibrosis in patients with carcinoid
tumors has thus become a critical quality-of-life issue, since symptom regulation and isotopic
and embolic control of tumor growth have increased life expectancy. The advantageous
outcomes of such therapy are negatively impacted by the consequences of this uncontrollable
neoplastic-driven desmoplastic response. While fibrosis is a ubiquitous process involved in
5

many different diseases , it is of particular importance in carcinoid patients, as survival and
quality-of-life issues have now become increasingly influenced by the development of
4

peritoneal and/or peripheral (cardiac) fibrosis . Serotonin has been implicated as the
mediator of the fibrosis associated with midgut carcinoids; however, no consistent
relationship between carcinoid-induced mesenteric fibrosis and elevated blood or tumor
6

levels of serotonin or bradykinin is evident . The responsible factor is thus unknown.
7

Connective tissue growth factor (CTGF) is a novel, cysteine-rich peptide , belonging
to a family of immediate-early genes that are especially needed for the coordination of
7

complex biologic processes such as differentiation and tissue repair . CTGF functions as a
downstream mediator of transforming growth factor beta 1 (TGFβ1 – a known regulator of
fibrosis) action in fibroblastic cells, and mediates some of the profibrotic activities of
TGFβ1. Recent studies suggest that TGFβ1 leads to the induction of CTGF, which acts in
concert with TGFβ1 to drive the overproduction of collagen, a critical determinant in
8

fibrosis . TGFβ1 has been identified in small bowel carcinoids and in cardiac autopsy
9

material . Whereas TGFβ1 plays an essential role in the initiation of fibrosis, it is the

8
persistent, TGFβ1-independent CTGF expression characteristic of fibrotic lesions that
bypasses the controls that normally suppress the wound healing response, resulting in
10

sustained, chronic, pathological fibrosis . Indeed, CTGF shows an expression pattern that
correlates with the severity of fibrosis; that is, CTGF expression is abundant in fibrotic
11

lesions, even in the absence of markedly elevated amounts of TGFβ1 ligand .
Because the association of small bowel carcinoid tumors with fibrosis and the
profibrotic effects of CTGF have been well-established, it is therefore plausible that this
bioactive peptide may be intrinsically involved in the regulation of carcinoid-related fibrosis.
To acquire preliminary data, CTGF mRNA levels in tumor tissue from patients with
carcinoids were examined and compared to levels found in non-tumor tissue from adjacent
sites in the same patients, when such tissue was available. Semi-quantitative polymerase
chain reaction (PCR) analysis demonstrated that significantly more carcinoid tumor tissue
specimens express CTGF message (16/19; 84%) compared to normal tissue (4/9; 44%)
(p<0.05). Of note, the three carcinoid tumors negative for CTGF message production were
all gastric in origin. Subsequent serum analysis of CTGF and TGFβ1 levels in patients with
carcinoid tumors, normals, and in patients with other diseases requiring surgery (e.g.
ulcerative colitis, colorectal cancer, hernia repair) demonstrated that both CTGF and TGFβ1
levels in patients with ileal carcinoids were significantly elevated (p<0.02) compared to
patients with other tumors. Furthermore, an examination of these two parameters revealed a
2

strong positive correlation between the two (R =0.81, p=0.0004), demonstrating that
CTGF and TGFβ1 are indeed co-secreted. CTGF levels correlated positively with serum
Chromogranin A (CgA) levels (a marker of carcinoid tumor size and disease activity)
(p=0.02), suggesting that CTGF may not only be a marker for fibrosis but a marker specific

9
to small bowel EC carcinoid tumors as well. Immunohistochemical examination of a
gastrointestinal carcinoid tissue microarray (TMA), comprised of tumor samples from thirtysix patients with carcinoids of the small bowel identified at Yale University over the last
twenty years (and presently the only carcinoid microarray in the United States),
demonstrated that 80% of carcinoids were both TGFβ1- and CTGF-positive, with a
correlation between staining of r=0.57 (p<0.0001).
Based on this preliminary data, I hypothesize that CTGF is over-expressed in small bowel
EC carcinoid tumors and is directly involved in the genesis of ileal carcinoid-related fibrosis. My
overall aim is to understand the role of CTGF in the mechanism of carcinoid fibrosis and
whether measuring serum levels of CTGF could facilitate the detection of such fibrosis, with
the ultimate goal of identifying a novel molecular target for therapeutic intervention in
fibrotic disease associated with carcinoid tumors. Furthermore, it is important to understand
why carcinoids derived from the enterochromaffin (EC) cell in the small bowel generate a
fibrotic response while carcinoid tumors elsewhere in the gastrointestinal tract do not. For
instance, it is well-known that gastric carcinoids derived from the gastric ECL cell,
12

irrespective of their metastatic potential, are never associated with fibrosis and therefore
constitute an ideal control group. The preliminary data demonstrated that the tissue and
serum CTGF levels in patients with gastric ECL cell carcinoids were low (<10 ng/ml). Since
carcinoid tumors in different parts of the gastrointestinal tract originate from different
endocrine cells and only small bowel (EC cell) carcinoids are associated with fibrosis,
determining whether CTGF is the secretory product of this tumor responsible for
engendering fibrosis, defining the mechanism by which it causes fibrosis, and identifying a
method by which the agent can be identified in tissue and serum could thus facilitate the early

10
detection or prediction of the likelihood of fibrosis. Since not all small bowel carcinoids are
associated with the same rate or degree of fibrosis, this could enable the determination of
important scientific as well as clinical information as to the risk of fibrosis in individual
patients. Identifying serum factors will enable the identification and monitoring of patients
liable to develop fibrosis.
No current strategies exist to treat fibrosis associated with small bowel carcinoids
13,14

except surgical intervention

. As such, the identification of a fibrotic mediator of small

bowel carcinoid-related fibrosis may allow for the identification of a specific molecular target
necessary to identify and develop novel therapeutic probes designed to obviate fibrosis.

11

12

Carcinoid Tumors: The Evolution of Our Understanding

Overview
Carcinoid tumors of the small bowel (midgut) are the most common (42%)
neuroendocrine tumor (NET) of the gastrointestinal (GI) tract. Derived from the serotoninsecreting enterochromaffin (EC) cell, small bowel carcinoid tumors are histologically as
diverse as the spectrum of substances they secrete. Densely packed with neurosecretory
granules containing hormones and biogenic amines, they can range from indolent,
15

unrecognized entities to highly active, metastatic secretory tumors . They are generally
advanced at diagnosis, and in most instances are only detected at surgery when hepatic
metastases have resulted in overt symptomatology or emergently for unexplained bowel
obstruction or bleeding. For the most part they tend to be associated with the gastrointestinal
tract and the bronchopulmonary system, though there is a substantial number of other sites
where these lesions may arise, including the esophagus, Meckel’s diverticulum, liver,
pancreas, and biliary tract; within the pelvic and oto-laryngeal organs; as well as within the
16

breast .

Preface
The historical data in this section pertaining to Dr. Siegfried Oberndorfer is entirely
novel and was collected over the course of a year from several sources, including meeting
personally with Dr. Oberndorfer’s grandson in Germany in June 2004, telephone
conversations with Oberndorfer’s daughter in Oslo in August 2004, and personal

13
correspondence with great-grandchildren in Medellín, Columbia and faculty members from
the Department of Pathology at the University of Istanbul. Furthermore, I translated an
autobiography that Dr. Oberndorfer had written in German a year before his death but never
published, and the biographical information presented in the thesis represents a distillation of
his own words. The German text was translated manually into English using free online
translation

software

(e.g.

AltaVista

Babel

Fish

Translation

tool;

http://babelfish.altavista.com).
The data detailing the evolution of the carcinoid concept, particularly the descriptions
th

of the earlier (19 century) observations (e.g. those of Langhans, Lubarsch, Notthafft,
Nicolas, etc.), were obtained by translating the text of the original German or French articles,
which I procured either in the Yale Historical Library or from the private collection of Dr.
Castrillón-Oberndorfer and translated manually as described above.
I designed all of the illustrations in this section. I obtained the collage elements from
their original sources in the Yale Historical Library or from the personal collection of Walter
Castrillón-Oberndorfer in Germany and designed each collage myself using Adobe
Photoshop software. Likewise, the schematic cartoons illustrating the proposed mechanisms
underlying the hypothesis were conceived of and prepared solely by me using Corel Draw
software. Photographs of gross pathological specimens and endoscopy findings were
obtained with permission from Dr. Modlin’s archived collection. Certain collages have been
published recently (e.g. figures 1, 2, 5, and 7 appear in Modlin IM, Shapiro MD, Kidd M.
Siegfried Oberndorfer—Origins and Perspectives of Carcinoid Tumors. Hum Pathol 2004;
35(12):1440-51).
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Historical Background of Carcinoid Tumors
With ever-increasing recognition and understanding of carcinoid tumors, little is
known about the lives of the men who first defined the tumor, described its distinct histology
and cell type, and the delineated the clinical hallmarks of the disease. Siegfried Oberndorfer
(1876-1944), a German pathologist at the University of Munich, first described the
idiosyncratic nature of these tumors and coined the term “carcinoid” in 1907. Such lesions
had actually been observed and documented earlier, however, by a number of physicians
17

during the nineteenth century, including Theodor Langhans in 1867 , Otto Lubarsch in
18

19

1888 , and William B. Ransom in 1890 .
Langhans, who at one time worked under F. Recklinghausen (1833-1910), was the
first to describe a carcinoid tumor that was found at autopsy in a fifty-year-old woman who
17

had died of tuberculosis . Langhans noticed a firm, mushroom-shaped submucosal tumor
that projected into the lumen of the small intestine, the borders of which were very sharp
without any evidence of peri-tumoral invasion (Figure 1). He noted how the tumor cells
resembled poorly-differentiated glandular tissue and were arranged in nests with a rich, thick
fibrous stroma. His 1867 manuscript detailed the histological features of the tumor, though
he never commented on the clinical and growth behaviors of this hitherto undocumented
neoplasm. The carcinoid tumor had been discovered, though twenty-one years would pass
before this obscure and unexplained entity was reintroduced into the medical literature by
Otto Lubarsch.

15

Figure 1: Theodor Langhans (1839-1915) (bottom right) was born in Usingen, Germany and studied medicine in
the universities of Heidelberg, Berlin, and Göttingen. He spent his early career as a pathologist in Würzburg, where
in 1862 he was made assistant to von Recklinghausen. Five years later, Langhans published the first report of a
carcinoid tumor that was found at autopsy in the small intestine of a 50-year-old woman (frontispiece, top left),
though this was merely a histological description of the tumor without any mention of its associated clinical behavior.
Langhans later studied the structure of the placenta in Marburg, where he also made significant contributions to the
pathology of nephritis, calling attention to the giant cell, which came to be known as the Langhans cell (bottom left).
He spent the majority of his career (40 years) at the University of Bern (background), working with the likes of T.
Kocher (1841-1917) and H. Sahli (1856-1933), and made major contributions to the understanding of the
pathological anatomy of goiter and cretinism, renal infections, blood pigments, and the placenta.

Lubarsch (1860-1933) of Berlin (Figure 2) conducted most of his early research in
various Institutes of Pathology throughout Switzerland. In 1888, at the age of 28, Lubarsch
18

described two cases of ileal tumors discovered at autopsy . In one case (49-year-old male),
the ileum contained numerous tubercular ulcers and nodules on the mucous membrane; the

16
second case (52-year-old male), also tubercular, described the presence of six scattered small

Figure 2: Otto Lubarsch (1860-1933) (top right) of Berlin studied philosophy and natural sciences in Leipzig and
Heidelberg and later earned his medical degree in Strasbourg in 1883. After working as an assistant at the Institute
of Physiology in Bern (top background) and at the Pathological Institutes of Giessen, Breslau, and Zurich, he became
Professor of Anatomy and Pathology at the Pathological Institute in Rostock in 1894. Well-known for his eponymous
characterization of tiny crystals found in the epithelial cells of the testis that resemble sperm crystals (“Lubarsch'
crystals”) and Lubarsch-Pick syndrome (systemic amyloidosis, primary, systematized amyloidosis, systematized
amyloidosis with macroglossia), he also provided the first detailed pathological description (lower left, background) of
carcinoid tumors while in Breslau in 1888, in which he reported multiple ileal carcinoid tumors on autopsy in two
male patients (frontispiece, center).

carcinomatous growths in the ileum and a cirrhosed liver. Interestingly, diarrhea had been a
prominent symptom in the latter patient, quite possibly as a manifestation of carcinoid
syndrome, though Lubarsch made no mention of metastatic disease in either case.
Microscopically, he noted a low-grade penetration of the tumor into the muscularis circularis
and hyperplasia of the muscularis mucosae. Lubarsch was reluctant to identify these lesions

17
as carcinomas, and after a careful search through the world’s literature he found records of
thirty-five cases of intestinal carcinomas occurring near the ileocecal valve. He was of the
opinion that several of these were not true carcinomas.
William Bramwell Ransom of Nottingham was the third to describe a lesion
19

resembling carcinoid tumors . In the November 1890 issue of The Lancet, Ransom
described a fifty-year-old woman who initially presented with two egg-sized lumps in the
lower part of her stomach, menorrhagia, and severe diarrhea. Her symptomatology was
mostly attributed to uterine fibroids, and her symptoms had only somewhat improved by the
time she left the hospital several weeks later. The diarrhea persisted for the next two years,
after which she presented with a large, palpable abdominal mass and substantial cachexia. Of
particular interest was the observation of severe attacks of wheezing and diarrhea upon
eating, arguably the first reported presence of carcinoid syndrome, which had hitherto
remained undocumented. Upon her death soon thereafter, autopsy revealed several small
nodules in the ileum, six inches above the ileocecal valve, along with extensive hepatic
metastases. The nodules were walnut-sized, and the tumor demonstrated rounded, polypoid
growth patterns without any ulceration or macroscopic changes to the mucosa. The tumor
cells were arranged in small nests that formed small tubes or solid bars, and hardly any
remains of villi or crypts of Lieberkühn were visible near the free surfaces of the tumor. As
with the two cases described by Lubarsch, Ransom noticed a hyperplasia of the muscularis
mucosae.

Ransom astutely noted that these tumors resembled carcinomas only

histologically, may remain undetected for a long time, and generally demonstrated very
slight, local malignancy or a tendency to infiltrate or destroy their surrounding tissues. He
proposed that their malignant potential was largely dependent on the local conditions (i.e.

18
vascular supply, resistance) of the peri-tumoral tissues. He referred to the tumors as
“glandular carcinomas”, although their peculiar appearance caused by penetrating blood
vessels into the tumor led him to propose a resemblance to cylindromas (uncommon benign
adnexal tumors).

In fact, he believed this angiogenesis was more consistent with the

behavior of sarcomas than with carcinomas. Ransom could only speculate, however, on the
etiology of these tumors and no definitive conclusions were made.
In 1895, A. Notthafft, an assistant at the Pathological Institute of Würzburg,
described three tumors of the upper jejunum found at autopsy in a patient who had died of
pneumonia. The first “pinhead-sized” tumor was found approximately 10 cm past the end of
the duodenum; the second and third tumors, both “pea-sized”, were found 10 cm and 15 cm
distal to the first tumor, respectively. They had a whitish color, hard consistency, and a
smooth surface. He noted rampant tumor growth in the submucosa, which rose strongly
over the level of the adjacent mucous membrane, and there was small cellular infiltration in
much of the adjacent mucous membranes and into the muscular layer. The tumors were
uncharacteristically identified in the submucosa and histologically not true carcinomas; he
20

thus referred to them as “beginning carcinomas” .
The carcinoid tumor then faded into obscurity once more, and twelve more years
passed before Oberndorfer’s initial unsuccessful attempt to characterize and delineate the
properties of this enigmatic neoplasm was presented.

Oberndorfer and Karzinoide
Oberndorfer first presented his observations on carcinoid tumors at the German
Pathological Society convention in Dresden in September 1907 and in December of the same

19

Figure 3: In September of 1907, Oberndorfer first presented his seminal work on carcinoid tumors at the German
Pathological Society meeting in Dresden, which he published three months later in the Frankfurt Journal of
Pathology (frontispiece, above right). He described six cases of multiple pea-sized ileal tumors in close proximity,
which grew extremely slowly and presumably without any metastatic potential (an observation he later refuted in
1929). Upon microscopic evaluation (lower right), however, the tumors featured the histological characteristics of
carcinomas (e.g. undifferentiated tissues surrounding the tumor cells). Oberndorfer successfully demonstrated that
this seemingly paradoxical finding was indeed a novel disease entity, and he assigned the name karzinoide
(“carcinoma-like”) to more accurately describe these tumors.

year, published his seminal paper “Carcinoid Tumors of the Small Intestine” in the Frankfurt

Journal of Pathology21. This manuscript was the first to describe and characterize the tumor
that had previously been referred to as a “benign carcinoma” (Figure 3).
The first case described a 48-year-old woman who had been presumed to have
perished as a result of tuberculosis. At autopsy, four pea-sized tumors were found in the
ileum, three of which were separated by approximately 20 cm along the intestine, while the
fourth tumor was only 1 cm distal to the third. Each tumor was found in the submucosa, and

20
the surrounding intestinal mucosa and neighboring serosa revealed no reactive inflammation.
The histological findings were consistent with those described by previous authors, in that
the lesions were arranged in nests of small polymorphic cells with large nuclei and scant
cytoplasm; there were distinguishable, albeit atrophic, crypts of Lieberkühn; dense, fibrous
connective tissue comprising the surrounding stroma and rampant epithelial vascular growth
was adjacent to the tumor. The mucosa and muscularis mucosae were completely intact, and
no cellular infiltration of the tumor into the surrounding stroma could be observed. In
addition, noticeable changes of the liver, kidney, and spleen were observed, all of which
exhibited high-grade amyloid degeneration, though it was unknown whether or not such
findings could be attributed to metastatic carcinoid disease or tuberculosis.
The second case involved a 30-year-old woman who had soon after the birth of a
child had died of typhoid fever. At autopsy, three small tumors, approximately the size of
peas, were found in the ileum. The first and second tumors were separated by approximately
30 cm, while the third was about 40-50 cm distal to the second tumor. The surrounding
stroma of each tumor was comprised of connective tissue and smooth muscle fibers, and
proliferation of glandular epithelium was noted. The four other cases reported similar
findings, and Oberndorfer noted some general trends. All tumors were located in the
submucosa of the ileum, the normal elements of the mucosa (particularly the crypts of
Lieberkühn) were almost completely absent, and the stromal tissue consisted of smooth
muscle fibers and connective tissue.
Although five of the six cases demonstrated undifferentiated tumor cells that would
generally be regarded as carcinomas, Oberndorfer recognized that their clinical behavior was
inconsistent with that of a “classical” carcinoma and concluded that these lesions were a

21
completely different clinical entity. He argued that large carcinomas of the small intestine
were extremely rare and he had never observed multiple large carcinomas of the small
intestine. He further asserted that a multiplicity of large identical tumors in the small
intestine had not previously been reported, and the considerable distance between the tumors
suggested that they were each primaries, since “metastatic hematogenous or lymphatic spread
could not account for the observed findings”. He further reasoned that if the tumors were to
be considered as multiple primary carcinomas of the intestine, they must adhere to the three
22

criteria proposed by Michelsohn in that:
1. The new formations must differ from each other morphologically and histologically.
2. Each carcinoma must be histogenetically derived from the epithelium of the mucosa.
3. Every tumor has the potential for metastasizing.
According to Oberndorfer, only the second criterion was fulfilled, and the third criterion was
omitted since metastases were not detectable in the cases he had examined. Furthermore, the
tendency of these tumors to grow very slowly distinguished them from the rapid, highly
invasive nature of carcinomas. As a result of his observations, Oberndorfer ascribed five
distinct characteristics to these tumors:
1. They are mostly small, with patients commonly demonstrating multiple tumors.
2. The tumor cells are usually surrounded by undifferentiated tissues, possibly
demonstrating gland formation.
3. The tumors have not previously been described, and they have the potential to
become invasive.
4. They do not metastasize.

22
5. They apparently grow extremely slowly, achieving no substantial size, and therefore
appear to have a harmless nature.
Given their “aberrant” characteristics, Oberndorfer asserted that such tumors could not be
categorized as any other small intestinal neoplasm and therefore represented a novel disease
entity.
Of paramount importance to Oberndorfer was determining whether these tumors
were actually true cancers. Although their histological appearance was consistent with a
malignant process, the clinical features suggested otherwise, as the lesions did not
demonstrate rapid growth, the tumor borders were sharply circumscribed, and they did not
appear to metastasize. Given that the classical understanding of a carcinoma did not appear
to encompass the behavior of the processes that he had observed in these tumors,
Oberndorfer reasoned that perhaps the term karzinoide (“carcinoma-like”) might more
accurately describe the lesions. Although Oberndorfer’s early contributions to the
understanding of the biology of carcinoid tumors were prescient, his assertion that the
tumors were of a benign nature subsequently proved to be incorrect. However, in 1929,
twenty-two years after first characterizing the carcinoid tumor, Oberndorfer described his
further experience with thirty-six carcinoid tumors of the appendix and small intestine. In
this manuscript, he revised his initial characterization of the benign behavior of the tumor
and confirmed the possibility that karzinoides might exhibit malignant features and
23

metastasize .

23
Cell of Origin: The Enterochromaffin (EC) Cell
Although progress had been made in elucidating the pathological nature of this “odd”
tumor of the small intestine, there was a paucity of information available regarding this
tumor’s cell of origin. W. M. Bayliss (1860-1924) and E. H. Starling (1866-1927)
24

provided the first scientific evidence that the gut was an endocrine organ in 1902 . But
much earlier in 1868, R. P. Heidenhain (1834-1897) of Breslau, Prussia found
enterochromaffin (EC) cells in the gastric mucosa, and in 1870 he first noted the existence of
25

enterochromaffin-like (ECL) cells, although he was not able to define their role . He noted
that such cells, distinguishable by their deep-yellow color when stained with bichromate
solutions, were simply morphologically different to other intestinal mucosal epithelial cells.
In 1897, Nikolai Kultschitzky of Russia noted similar cells in the crypts of Lieberkuhn in the
26

intestinal mucosa .
28

27

Similar observations were made by A. Nicolas (1891) , H. Kull
29

(1924) , and M.C. Ciaccio , the latter of whom introduced the term “enterochromaffin” in
1906.

In 1914, A. Gosset (1872-1944) and P. Masson (1880-1959), using silver

impregnation techniques, demonstrated the argentaffin-staining properties of carcinoid
30

tumors (Figure 4) and suggested that these neoplasms might arise from EC cells.
Subsequent studies demonstrated that carcinoid tumor cells indeed displayed
characteristic light microscopy and histochemical features in their reactions with silver salts
(e.g. argentaffinity and argyrophilia). In 1938, Friederich Feyrter (1895-1973), Professor of
Pathology at the Medical Academy of Danzig, Poland, proposed that carcinoid tumors were
31

derived from the diffuse endocrine system . He based this proposal on the observation of
argentaffin-positive and argyrophilic “clear cells” (helle zellen) throughout the gut and
32

pancreas that failed to take up conventional stains . By 1948, A. B. Dawson had developed a
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Figure 4: Pierre Masson (above right) of Dijon studied medicine in Paris, and after earning his degree in 1909
continued his studies at the Pasteur Institute until 1914. By the end of World War I, his reputation as a
histopathologist was so great that, despite his youthful age and inexperience, he was offered the Chair of Pathology at
the University of Strasbourg. He attained notoriety with the pioneering development of his eponymous trichome stain,
which became the standard in all pathology laboratories. This innovative technique allowed him and A. Gosset (lower
left) to demonstrate in 1914 the argentaffin staining properties of carcinoid tumors (frontispiece, center). They
suggested that the Kulchitsky, or enterochromaffin (EC) cells in the gut (background), which had been earlier
discovered in 1897 by Nikolai Kulchitsky within the crypts of Lieberkühn in the intestinal mucosa, formed a diffuse
endocrine organ. In 1928, they described these cells as being of neural origin, and proposed that they were the
progenitors of neuroendocrine tumors of the gut (carcinoids). By 1927, Masson was invited by the Université de
Montréal to assume the role of Chair of the Department of Pathology, a position he held until his retirement in
1954.

technique by which EC and ECL cells of the gastrointestinal tract could be stained with silver
33

nitrate . Serotonin, or 5-hydroxytryptamine (5-HT), was described and isolated by M.
34

Rapport in 1948 . In 1952, V. Erspamer and B. Asero of Milan, both working in the
Department of Pharmacology at the University of Bari, isolated 5-HT in the EC cells of

Octopus and Discoglossus tissues and suggested that “enteramine” (serotonin) was the
35

specific hormone of the EC cell system . The Octopus vulgaris, a common native polyp, and

25
the Discoglossus pictus, an amphibian of Sicily and Sardinia, were both readily available and
particularly useful because their tissues and organs were especially rich in enteramine. In
1953, F. Lembeck (1922- ) of Graz biochemically confirmed the presence of 5-HT in an ileal
36

carcinoid tumor , corroborating the assumption that human EC cells contained this bioactive
amine.

Histopathological Classification
In 1966, Anthony Pearse (1916-2003) recognized that the endocrine cells of the gut
were linked together by a group of common cytochemical characteristics; in particular, the
uptake of 5-hydroxytrytophan (5-HTP) and its decarboxylation to 5-HT was analogous in
37

this distinct population of endocrine cells . By 1968, these peptide hormone-producing
cells, all of which presumably derived from the neural crest, were collectively known as
38

“amine precursor uptake and Decarboxylation” (APUD) cells . Since that time, the definition
of these cells has been modified somewhat, and they are now known as the “diffuse
neuroendocrine system” (DNES) (Figure 5). Although Pearse and others initially suggested
that APUD cells were derived from neural crest cells, it is now generally recognized that
39

40

gastroenteropancreatic APUD cells probably arise from endoderm . Le Douarin and Dupin

later demonstrated the multipotency of neural crest cells and proposed that enteric
gangliogenesis by neural crest cells reflected the effects of multiple growth factors of the glialderived neurotrophic factor family, as well as the endothelin-3/endothelin receptor B
41

pathway. More recently, Chalazonitis et al. reported that differentiation of various enteric
neurons is also regulated by neurotrophin-3.
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Figure 5: The first description of what has now come to be known as the “diffuse neuroendocrine system” (DNES)
was provided in 1938 by Friedrich Feyrter (left), then Professor of Pathology at the Medical Academy of Danzig. He
recognized the presence of argentaffin or argyrophil “clear cells” (helle zellen) in the gut and pancreas, and proposed
that such cells were the source of hormones that acted locally (frontispiece, top left). In the 1960s, A.G. Everson
Pearse (1916-2003) (below right), a histochemist at the Royal Postgraduate Medical School in London,
demonstrated that the cells described by Feyrter shared many functional characteristics with cells in many of the
major endocrine glands, such as the thyroid and hypothalamus. All were associated with the metabolism of amines
and the secretion of peptides and were thus conveniently described by the acronym APUD (amine precursor uptake
and decarboxylation) (center). Pearse’s work was instrumental in confirming the concept of a single neuroendocrine
system that populated the tissues of the body and was particularly conspicuous in the gastrointestinal tract.

Another ubiquitous yet inconsistently defined histopathological classification of
carcinoid tumors in the literature is the “typical” versus “atypical” designation, usually in
reference to their degree of differentiation. “Typical” carcinoids, by definition, are tumors
with neuroendocrine differentiation and characteristic histological architecture of trabecular,
insular, or ribbon-like cell clusters, with no or minimal cellular pleomorphism and sparse
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mitoses . “Atypical” carcinoids, however, demonstrate a more aggressive, poorlydifferentiated phenotype with increased mitotic activity and an absence or limited extent of
43

necrosis .
Recently, more sophisticated methods of analysis have facilitated the development of
precise classification systems that can discern the motley assortment of peptides and amines
present in carcinoid tumors.

As many as forty different secretory products have been
44

identified in the different varieties of carcinoid tumors . Ultrastructural findings of
intracytoplasmic electron-dense secretory granules and immunoreactivity with antibodies to
45

Chromogranin A are useful tools for confirming the diagnosis of carcinoid tumors .

Embryological Classification
Carcinoid tumors are commonly classified by their embryonic gut origin; an archaic
but somewhat useful distinction, since the features of carcinoid tumors derived from each
respective location differ clinically, histologically, and immunochemically. In 1963, E. D.
Williams and M. Sandler proposed the original classification of carcinoid tumors based on
46

their putative embryologic origin (e.g. foregut, midgut, or hindgut) . In 1971, J. Soga and
Y. Yakuwa introduced a histological classification based purely on morphological
characteristics, describing carcinoid tumors according to their dominant growth patterns:
47

insular, trabecular, glandular, mixed, or undifferentiated .
Although carcinoid tumors have historically been classified according to the foregut,
midgut, or hindgut derivation, this stratification was developed before the elucidation of the
different NE cell types and the appreciation that an embryologic classification had little
48

mechanistic or physiological validity . Unfortunately, this historical classification predates
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the understanding of the different cell types responsible for the broad group of tumors
generically grouped as carcinoids and has thus hindered the appreciation of the divergent
biological and pathological behavior of the individual tumors and their various respective
secreted peptides and amines. Broadly speaking, it has been accepted that foregut endocrine
cells give rise to carcinoid tumors in the respiratory tract, stomach, first part of the
duodenum, and pancreas; midgut carcinoid tumors represent lesions of the bowel from the
second part of the duodenum through the ascending colon and appendix; and hindgut
carcinoids constitute lesions of the transverse and descending colon and rectum. Carcinoid
tumors from different segments of the embryologic gut typically vary widely in terms of the
character of their bioactive products, and these differences result in a wide range of clinical
symptoms and immunohistochemical staining patterns. Variations in anatomic location and
venous drainage may further alter the clinical presentation. Midgut tumors most commonly
produce serotonin and tachykinins and often cause systemic symptoms (e.g. diarrhea,
flushing, wheezing, right-sided valvular disease, and cutaneous telangiectasia) once the
tumor has metastasized to the liver, or in rare instances following drainage of the tumor’s
bioactive peptides directly into the systemic circulation. An exception to this is the
appendiceal carcinoid, which is a relatively benign lesion (more neural than endocrine in its
49

biological behavior) that rarely produces serotonin .

Epidemiology
Carcinoid tumors are relatively uncommon, with an overall incidence of 1-to-2 per
51

100,000 people in the United States and comprise only 0.49% of all malignancies . A recent
series of nearly 14,000 carcinoids noted that the overall male-to-female ratio for carcinoid of
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the small intestine is 1.1:1 . Incidence among white males is 0.88 per 100,000 people per
year (1.65 among African-American males), while incidence among white females is
somewhat lower, with an analogous increased incidence among African-American females:
51

0.63 and 1.15 per 100,000 people per year, respectively .
In contrast to the better survival rates for carcinoids of the stomach, duodenum or
rectum (>80%), patients with jejuno-ileal carcinoids have a relatively poor 5-year survival
51

rate (55%) . The discrepancy is probably related to the earlier detection of the former, as the
symptomatology of any local lesion (dyspepsia or bleeding) leads to endoscopy, while EC
carcinoids do not usually become symptomatic until they have metastasized and actively
50

secrete bioactive products into the systemic circulation . The poor prognosis also reflects the
malignant behavior of the tumor with a high propensity to disseminate to both lymph nodes
and the liver.
Over 60% of carcinoids arise along the gastrointestinal tract; particularly the small
51

intestine, appendix, and colon , a reflection of the dense neuroendocrine cell population of
the gut and the conglomeration of “regulatory cells” necessary to sample and regulate the gut
environmental milieu (Figure 6). Similarly, the bronchopulmonary system possesses a
respiratory epithelium densely populated with Kultschitsky cells and accounts for
approximately 25% of carcinoid tumors, comprising roughly 2% of all primary lung
52

tumors .
Because of their slow-growing nature, most carcinoid tumors never spread beyond
the confines of the primary lesion and are often found incidentally during surgery or
4

autopsy . However, despite their indolent behavior, these lesions are by no means benign
and are histologically similar to carcinomas, which have the potential to become invasive and
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Figure 6: The majority of carcinoid tumors (over 60%) are found in the gastrointestinal tract, with the lung
being the second most common site (24.5%) of primary tumors.

give rise to extensive nodal and hepatic metastases. Their metastatic potential has been found
to be directly proportional to the size of the primary lesion, with only 2% of small bowel
lesions less than 1 cm in diameter showing metastases in one series, while approximately
53

80% of tumors with a diameter of 2 cm or more demonstrated metastases . A recent series
noted that 44% of patients with primary tumors less than 1 cm in diameter had evidence of
metastatic spread to the lymph nodes, while those with tumors 1-2 cm and >2 cm in size
demonstrated evidence of lymphatic metastatic spread in 77% and 85% of cases,
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respectively . The most common initial diagnosis among patients with small bowel
carcinoids is mechanical small bowel obstruction of unspecified cause, which occurs in 2025% of patients with these tumors

55,56

.
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Carcinoids and Clinicians

Carcinoid Syndrome
The constellation of symptoms including, but not limited to, edema, flushing, and
diarrhea, now commonly referred to as the “carcinoid syndrome”, was first described in 1931
57

by A. J. Scholte , a Dutch pathologist who documented at autopsy a 1 cm ileal carcinoid
tumor in a 47-year-old male who had suffered from diarrhea, cyanosis, cough, lower
extremity edema, and cutaneous telangiectasia before dying from cardiac failure and
bronchopneumonia. In the same year, M. A. Cassidy reported a patient who complained of
flushing and diarrhea before his death; autopsy revealed the presence of metastatic
58

“adenocarcinoma” and cardiac valvular lesions . Although Cassidy did not provide an
adequate histological description of the tumor tissue to confirm that these lesions were
carcinoids, his manuscript included a picture of the patient’s face that clearly illustrates a
flushed appearance consistent with the carcinoid syndrome (Figure 7). In 1943, S. Millman
described a 44-year-old female patient with flushing who on autopsy was found to have
59

multiple ileal carcinoids with metastatic spread to the liver and lymph nodes . In 1954, A.
Thorson and his colleagues

60

of Malmö, Sweden published the first series of patients

presenting with pulmonary stenosis, tricuspid insufficiency, peripheral vasomotor symptoms,
bronchoconstriction, and cyanosis in association with malignant carcinoid tumors of the
small intestine with metastatic spread to the liver. The report presented 7 "definite" cases, 4
"probable" cases, and 5 cases with partial or not fully verified symptoms, and their
symptomatology was related to the hypersecretion of 5-HT from the carcinoid tumors into
the systemic circulation. In the same year, B. Pernow and J. Waldenström, also of Sweden,
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Figure 7: Cassidy in 1931 described a patient who complained of flushing and diarrhea; a picture of his patient
(right) demonstrates the classic facial flushing associated with carcinoid syndrome. Biörck and his colleagues of
Sweden were among the first to describe the carcinoid syndrome (“carcinoidosis”) in 1952 (frontispiece, top), which
they characterized as a constellation of symptoms associated with abnormally high levels of plasma serotonin (center)
including flushing, diarrhea, edema, wheezing, and right-sided heart failure, the latter of which results from the
deposition of fibrotic subendocardial plaques (bottom left; fibrotic plaques stained pink) and is commonly referred to as
“carcinoid heart disease”.
61

added paroxysmal flushing as a key component of this syndrome . In 1964, J. A. Oates
demonstrated that some carcinoid tumors release kallikrein (which activates bradykinin, a
potent vasodilator) and suggested that kallikrein might also play a role in the flushing
62

episodes so characteristic of the disease .
In 1952, G. Biörck described carcinoid heart disease in a 19-year-old boy suffering
63

from pulmonary stenosis with tricuspid insufficiency and cyanosis . The patient was
dyspneic at rest and died while undergoing an angiogram, with electrocardiography
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demonstrating slow contractions of a very broad bundle branch block type. Autopsy revealed
a malignant carcinoid in the jejunum with extensive hepatic metastases. This report was
among the first to describe both pulmonary stenosis and tricuspid insufficiency in the
presence of carcinoid tumors.
Carcinoid syndrome is reported to occur in up to 18% of patients with midgut
64

carcinoids . The presence of the carcinoid syndrome generally implies that the patient has
liver metastases

65-67

, although symptoms may also occur at earlier disease stages owing to

mesenteric metastases and fibrosis, which may cause obstruction and ischemia of the
65

intestine . Extensive liver metastases without the presence of carcinoid syndrome, though
rare, may occur, suggesting a non-secretory behavior of certain tumors that may not
necessarily be of EC cell origin. An association with other non-carcinoid neoplasms is evident
in 16.6% of distal small bowel carcinoids and constitutes the largest percentage of such co68

morbidity among all gastrointestinal carcinoids . This aspect of the lesion presumably
reflects its production of growth factors that regulate cell proliferation.

Biochemical Markers
Carcinoid tumor cells are densely packed with neurosecretory granules containing
various hormones and biogenic amines. Carcinoid tumors can be diagnosed and monitored
by measuring a variety of bioactive peptides that are commonly secreted from the tumors into
the blood, including serotonin (5-HT), Chromogranin A (CgA), substance P, histamine,
dopamine, neurotensin, prostaglandins and kallikrein. The measurement of general and
specific biochemical markers in patients with carcinoids gives an indication of the
69

effectiveness of treatment and may be used as prognostic indicators .
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The utility of 5-HT as a plasma marker for carcinoid syndrome was first
demonstrated by I. H. Page in 1954, based on his observation of elevated urinary excretion
70

of the main 5-HT metabolite, 5-HIAA, in a patient with carcinoid syndrome . Subsequently
in 1956, B. J. Haverback and A. Sjoerdsma confirmed this finding in a series of 11 patients
with carcinoid syndrome, all of whom displayed markedly elevated levels of urinary 5-HIAA
71

over a 24-hour period . In 1957, B. Pernow of Stockholm provided definitive evidence to
explain this phenomenon by measuring serum 5-HT and urinary 5-HIAA levels in 33
72

patients with abdominal carcinoid tumors . Among the patients examined before operation
or after complete tumor resection, increased serum or urinary 5-HT levels were noted in 17
of 18 cases, and abnormally high 5-HIAA levels were found in 19 of 20 cases.
CgA is a member of the chromogranin family, which consists of at least three
different water-soluble acidic glycoproteins (CgA, CgB and CgC) stored in the secretory
granules of NE cells. CgA is a constitutive secretory product of most NETs. Its detection in
plasma can be utilized as a general tumor marker for carcinoids, and its concentration
73

correlates with tumor burden . Plasma CgA levels are sensitive but non-specific markers of
carcinoid tumors since they are also elevated in pancreatic NE tumors, as well as in other
74

types of NE tumors . Elevated CgA concentrations are not always specific for NETs, as
prostatic carcinoma can be associated with elevated CgA concentrations. However, current
assessment of prostatic tumors suggests that some lesions may have a substantial NE
75

component . False-positive increased CgA concentrations can be seen in renal impairment,
76

liver failure, atrophic gastritis and inflammatory bowel disease . Exercise, trauma-induced
physical stress, or untreated hypertension can also produce higher concentrations of CgA
73

than in the normal, resting state .
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Diagnostic Imaging
Carcinoid tumors have high
concentrations

of

somatostatin

receptors and can therefore be imaged
and

specifically

localized

somatostatin-receptor

with

scintigraphy

using a radiolabeled form of the
somatostatin
111

analogue

octreotide
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( indium

pentetreotide) .

diagnostic

modality,

This

commonly
®

known as the Octreoscan , has the
advantage of instantaneous whole

Figures 8 and 9: Octreoscan® in a patient with metastatic
carcinoid disease. Radiolabeled octreotide binds to
somatostatin receptors, which are found in abundance on
carcinoid tumor cells, and enables clinicians to detect the
presence and extent of carcinoid disease. The extent of
widespread disease, as seen above in this patient with
multiple hepatic metastases, can be visualized fully and
quickly with this diagnostic modality.

body scanning, which also allows
detection of distant metastases.

The
®

overall sensitivity of Octreoscan

is
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about 80% to 90% , and it is effective
in detecting primary and metastatic
lesions not apparent by conventional
radiological

imaging

techniques

(Figures 8 and 9).
Alternatively,

upper

GI

endoscopy can identify lesions as far as

Figure 10: Gastric carcinoid tumor, as visualized by
upper endoscopy. Photo obtained with permission from
Dr. Irvin Modlin.
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the ligament of Treitz and lower endoscopy can detect some terminal ileal tumors as well as
colorectal carcinoids (Figure 10). Luminal examination has been augmented by computerassisted tomography (CT) scanning and magnetic resonance imaging (MRI). In the last
®

decade, however, the Octreoscan has become the most widely used diagnostic technique and
should be used as the primary imaging method in patients with carcinoid tumors.
The presence of carcinoid heart disease can be assessed with transthoracic
echocardiography. Thickening and retraction of immobile tricuspid valve leaflets with
associated severe tricuspid valve regurgitation are characteristic echocardiographic features of
79

advanced carcinoid heart disease .

Treatment Strategies
Patients with small bowel carcinoid tumors generally have poorer 5-year survival
160

rates than those with carcinoid tumors in other GI locations . This reflects both the
relatively aggressive nature of small intestinal EC cell proliferation and the cryptic nature of
their initial clinical presentation. Surgical, interventional radiological, pharmacological, and
chemotherapeutic strategies have all been employed in the treatment of patients with
carcinoids, but for patients with fibrosis, surgery has thus far been the most logical choice
since no agents exist that are able to alter the progression of fibrosis.
Recently, the management of carcinoid tumors with pharmacological and
chemotherapeutic agents has increased patient survival. The somatostatin analogue
octreotide, a synthetic octapeptide that binds to the somatostatin subtype-2 receptor, inhibits
the secretion of bioactive substances, most notably serotonin, that cause the carcinoid
79

syndrome . The presence of functional somatostatin receptors in carcinoid tumors, and the
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suppressive effect of somatostatin on the active substances secreted by these tumors (e.g.
serotonin, tachykinins), provides the pharmacological rationale for using somatostatin
80

analogues to treat the symptoms associated with carcinoid syndrome . While treatment with
81

octreotide relieves symptoms in more than 70% of patients , this therapy does not prevent
the progression of cardiac fibrotic lesions, which developed in six of nine patients treated in a
90

recent study . Furthermore, many patients become refractory to this palliative therapy over
82

time , and despite a dramatic amelioration in symptoms there are no reports that
somatostatin analogues have any influence on fibrosis. In addition, a combination of
octreotide and hepatic artery embolization had no significant effect on the development or
90

progression of these lesions . Of note was the fact that this study also identified that patients
treated with cytotoxic chemotherapy exhibit an increased risk of progressive carcinoid-related
90

cardiac lesions .
For inoperable, well-differentiated, metastatic neuroendocrine tumors, biotherapy
83

with somatostatin analogs or interferon-alpha is the treatment of choice , which is able to
control both symptoms in functional tumor disease and tumor proliferation. Chemotherapy
has been limited to well-differentiated tumors of the foregut, which are relatively sensitive to
this treatment mode, and to the rarer, undifferentiated neuroendocrine tumors which are
often unresponsive to biotherapy

84,85

. In a recent prospective, randomized, multicenter study,

patients with metastatic gastroenteropancreatic tumors demonstrated similar responses
(partial remission or stable disease over a 12 month period) when treated with either
86

somatostatin (32%), interferon-alpha (30%) and a combination of the two (25%) .
Interestingly, there were no differences in outcome for either functional or non-functional
disease. Progression of disease was, however, noted in greater than 50% of patients.
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The only current therapy for fibrotic carcinoid tumors or carcinoid heart disease is
92

surgery . In one study, a dissectional removal of mesenteric tumors resulted in a substantial
symptomatic relief

92

. More often than not this is impossible and leads to multiple

enterotomies or mesenteric devascularization and ischemic bowel infarction. Surgical
87

debulking of the hepatic disease has been shown to improve survival , but current
recommendations indicate that the removal of 90% of the disease is required to achieve
88

palliation in these patients . In one recent retrospective examination of patients undergoing
89

surgery at the Mayo Clinic , it was found that although an operation controlled symptoms in
104 out of 108 patients, the recurrence rate was 59% at 5 years, and the five-year survival
was 35%. Surgical curative treatment of neuroendocrine tumor disease can only be achieved
in patients with small primary tumors or tumors with limited local disease.
While cardiac valvular surgery may be appropriate for patients with carcinoid heart
disease in certain cases, a hepatic artery embolization approach failed to significantly affect
90

carcinoid heart disease in one study . The direct dissectional approach and targeting the liver
metastasis will both conceivably decrease the biochemical symptomatology associated with
the disease, but the long-term effects on fibrosis are not known.
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Carcinoid Tumors and Fibrosis

Overview of Carcinoid-Related Fibrosis
Because of their inconspicuous size and deep submucosal location, primary carcinoid
tumors are rarely diagnosed before metastases have developed and patients thus often present
with advanced disease. When these tumors manifest clinically, it is most commonly the result
of extensive fibrosis around the tumor that often extends throughout the peritoneal cavity.
Such fibrosis ultimately leads to intestinal obstruction caused by either kinking of fibrous
adhesions of intestinal loops, luminal obstruction by fibrosis within the tumor, or
91

intussusception—all of which warrant surgical intervention (Figure 11).
Fibrosis within the abdomen may also contribute to significant bowel ischemia and
infarction. Patients with carcinoid tumors often suffer from intestinal venous ischemia and
partial or complete intestinal obstruction, commonly associated with abdominal pain,
92

aggravated diarrhea, malnutrition, and general malaise . The fibrosis around mesenteric
metastases often causes shrinkage and fixation of the ileal mesentery to the retroperitoneum,
with fibrous bands of tumor often attaching to and possibly obstructing the small intestine
92

and transverse colon . Furthermore, the consequences of retroperitoneal fibrosis may include
93,94

stenosis of the ureters, with associated hydronephrosis and renal failure in several cases

.

Marked vascular damage from the fibrosis may occur if mesenteric vessels and nerves become
trapped in dense deposits of peri-tumoral fibrous tissue, and this may lead to bowel
91

(particularly small bowel) ischemia (Figures 12 and 13).
The relationship between small bowel carcinoids and fibrosis has been well
92,95-101

documented in the literature

, yet the mechanism by which the tumors stimulate fibrosis
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remains poorly understood. Moertel and his colleagues first described the unique relationship
95

between carcinoids and fibrosis in 1961 , with particular attention to the fact that
obstruction is usually the initial symptom in most patients with carcinoid tumors of the small
intestine. Ohrvall further noted that approximately half of the patients with metastatic
carcinoids initially presented with and required surgery for intestinal obstruction or acute
92

abdominal pain, often with an unknown diagnosis . In contrast, Delbridge in 1996 asserted
that many surgeons faced with the patient with metastatic midgut carcinoid disease should
take a nihilistic approach and only reluctantly offer surgery as a form of therapy, opting
instead to wait until the development of severe symptoms of obstruction or ischemia before
102

contemplating laparotomy . Thus, while carcinoid tumors themselves are usually (but not
always) slow-growing, the fibrosis associated with these tumors eventually leads to major
complications that require surgical intervention and accounts for the significant morbidity
and mortality associated with carcinoid disease.

Incidence of Carcinoid-Related Fibrosis
Moertel and his colleagues presented one of the earliest retrospective analyses midgut
95

carcinoid tumors with his series of 209 cases . Of these, one hundred and thirty-seven
carcinoid cases (65.5%) were identified at autopsy and 72 cases (34.5%) were identified at
laparotomy. In Morgan’s series of 37 patients with jejuno-ileal carcinoids, 8 of 12 patients
103

with obstruction had fibrosis or bowel kinking . The chief, and sometimes only, clinical
symptom that patients presented with were the result of partial or intermittent intestinal
obstruction, and 48 of 56 patients (85.7%) who presented with symptomatic lesions had
metastatic disease at diagnosis. In a series of 262 patients with carcinoid tumors who
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underwent surgery before diagnosis, 121 (46%) presented with severe abdominal pain and
104

intestinal obstruction . In a review of 36 patients with small bowel carcinoids at Yale
University (1972-2001), fifteen patients (42%) either subsequently developed or had
105

documented fibrosis at time of operation .

Clinical Features
Symptoms of bowel obstruction are not always due to peritoneal fibrosis or an
obstructing tumor, and this caveat should be borne in mind when interpreting medical versus
surgical series. In the latter, the etiopathogenesis of the pain can often only be directly proven
by exploration. In a surgical series of 121 patients with midgut carcinoid tumors, 75
(61.9%) developed abdominal pain and required laparotomy; among these patients, marked
104

mesenteric fibrosis was detected at surgery in 59 (78.6%) . The mesenteric fibrosis among
these patients was generally accompanied by symptoms of intestinal obstruction, including
feeding-related or crampy abdominal pain, cessation of diarrhea, and weight loss. Of these
patients, 90% suffered from acute abdominal pain, 58% developed weight loss (>9 kg), 56%
had a palpable lower abdominal mass, and 39% had experienced cessation of diarrhea even
leading to episodes of constipation.
In medical studies, abdominal pain was the initial symptom in most patients,
described as episodic, colicky pain associated with distension and characteristic of
157

intermittent intestinal obstruction . Cai and his colleagues described a case of ileal carcinoid
106

in a 74-year-old woman who presented with a small bowel obstruction requiring resection ;
she reported abdominal pain of one month’s duration and her clinical exam revealed a
palpable mass in her right lower quadrant.

43
Approximately 5% of midgut carcinoid patients exhibit military seeding in the intra
abdominal cavity, reflecting the facility with which carcinoid tumors can seed and grow
locally. Many of these patients develop a “frozen” abdomen and pelvis, despite the absence of
104

bulky liver metastases . Although this disease form frequently presents with obstruction, it
is not necessarily always associated with fibrosis.

Retroperitoneal Fibrosis
Once the primary tumor invades the muscular layer of the small bowel and spreads
into the peritoneum and mesentery, a considerable fibrotic reaction occurs that may mat or
buckle multiple loops of bowel together, often leading to kinking of the bowel, intestinal
ischemia, volvulus, or obstruction of the lumen. By this time the patient usually has advanced
disease and becomes symptomatic, most often presenting with intermittent, feeding-related
53,106

abdominal pain, weight loss, and a palpable abdominal mass

. At this point, surgical

attention is imperative, since the fibrosis associated with the tumors tends to cause
compression and sclerosis of the mesenteric vessels, with one-third of patients with advanced
midgut carcinoids subjected to laparotomy demonstrating intestinal venous ischemia or
92

congestion . Anthony and Drury demonstrated elastic vascular sclerosis in 17 of 25 patients
107

with ileal carcinoids . Surgery has been reported to provide durable, long-term symptom
92

relief and substantial periods of survival among these patients . Among patients with
metastatic spread, resection of mesenteric lymph nodes and/or liver metastases resulted in
alleviation of symptoms and increased survival in two large series.

Carcinoid Heart Disease
Carcinoid heart disease is a unique and dangerous component of EC tumors. It
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represents a serious clinical condition, and one-third of all deaths in patients with carcinoid
syndrome are related to right ventricular failure secondary to cardiac morphological changes
108

(e.g. stenosis of the tricuspid and pulmonary valve) . The lesions are located on the mural
and valvular endocardium, predominantly in the right side of the heart, and consist of
fibroblasts or myofibroblasts and a matrix-rich fibrous stroma devoid of elastic fibers covered
109

by endothelium

(Figure 14). Right-sided valve dysfunction is attributed to the presence of
110

carcinoid plaques, which cause both thickening and retraction of the valve .
92

The most widely accepted therapy for carcinoid heart disease is surgery , which may
improve symptoms and longevity, but the scarce data report an early mortality of 35% to
111,112

53%

. However, a recent study reported that the excision of mesenteric tumors resulted
113

in a substantial symptomatic relief . However, more often than not this is not feasible and
leads to either multiple enterotomies or mesenteric devascularization and subsequent
ischemic bowel infarction. Surgical debulking of hepatic disease has been shown to improve
114

survival , but current recommendations indicate that the removal of 90% of the disease is
115

required to achieve palliation . A recent retrospective examination of patients undergoing
surgery at the Mayo Clinic

116

noted that although resection “controlled” symptoms in 104

out of 108 patients, the recurrence rate was 59% at 5 years, and the 5-year survival rate was
35%. The authors concluded that surgical curative treatment of neuroendocrine tumor
disease can only be achieved in patients with small primary neuroendocrine tumors or tumors
with limited local disease. The effect of removal of the primary lesion on the evolution of
cardiac heart disease is at this time unclear. The use of balloon pulmonary valvuloplasty in
conjunction with cardiac catheterization has been proposed as a palliative measure for
117

symptomatic patients with carcinoid heart disease , while the use of hepatic artery
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embolization to impede the progression of carcinoid heart disease failed to prevent the
118

development of cardiac lesions in one study .
The prevalence of carcinoid heart disease is increasing due to prolonged life
expectancy of patients, secondary to improved treatment protocols of carcinoid tumors. The
119

prevalence of cardiac heart disease has been noted to be 20% , while abnormal tricuspid
3

function was identified in 33% of patients and valvular lesions seen in 53 of 138 (38%) of
120

cases .
Historically, the etiology of the cardiac lesions has been considered to be due to excess
53

serotonin that was not degraded by monoamine oxidase (MAO) in the lungs . However, no
clinical studies have rigorously examined the direct relationship between circulating serotonin
levels to assess whether the agent is actually responsible for the fibrosis. An initial study in
1985 reported that there was no correlation between 5-hydroxyindoleacetic acid (5-HIAA),
121

the byproduct of serotonin degradation, and the extent of the heart disease . Thereafter,
numerous authors have proposed a link between 5-HIAA and/or tachykinins and cardiac
fibrosis

122,123

. A cardiac threshold for circulating serotonin of 400-500 μM has been proposed

as a minimum concentration required for the development of valvular lesions

125,124

. However,

treatment resulting in significant reductions of urinary levels of 5-HIAA, with no regression
125

of the cardiac manifestations in carcinoid syndrome, has been observed . A recent study
linking 5-HIAA to carcinoid heart disease speculated that another as yet unidentified agent
produced by carcinoid tumors probably participated directly or indirectly in the development
90

of these fibrotic lesions . Thus, although the etiology of both intestinal and cardiac fibrotic
lesions remains unknown, it seems plausible that their genesis reflects the biological effects of
a common agonist. Any hypothesis relating tumor product to fibrosis in either of these areas
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needs to include and reflect, apart from serotonin and tachykinins, the consideration of other
growth regulatory products from the tumor cell.

Pulmonary Fibrosis
126

Pulmonary carcinoids comprise approximately 2% of primary lung tumors , and of
160

all carcinoid tumors, 25% are found in the lungs . Pulmonary fibrosis has been reported in
association with carcinoid tumors, commonly in the setting of advanced metastatic
127,128

disease

. Furthermore, Moss and his colleagues noted that in a series of 50 patients with

carcinoid syndrome, 9 (18%) had “idiopathic” pleural thickening although no underlying
128

cause for these pleural abnormalities could be identified . Individuals with bronchial
carcinoid tumors can develop left-sided valvular lesions, as the tumors may secrete bioactive
agents into pulmonary venous effluent, bypassing the liver and lungs, where amines and
129

peptides are usually metabolized .

Carcinoid-Related Scleroderma
Cutaneous flushing, most commonly of the face, neck, and upper chest, are hallmark
features of the carcinoid syndrome. This flushing may persist for 10 to 30 minutes and tends
130

to first resolve centrally, producing gyrate and serpiginous patterns . Of interest, however,
is cutaneous fibrotic disease, particularly a scleroderma-like manifestation, which was first
noted in association with carcinoid syndrome in 1958 in a 42-year-old female with atypical
131

scleroderma and symptoms of carcinoid syndrome . On autopsy she was noted to have an
ileal carcinoid tumor. Subsequently a number of reports have confirmed the initial
observation and documented the relationship of carcinoid-related scleroderma, mostly
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affecting the lower extremities and usually associated with primary tumors of midgut
origin

132-136

.

The underlying biology of the relationship between small bowel carcinoid tumors and
fibrosis (at any site) thus remains unknown but presumably reflects the bioactivity of a
secreted systemic mediator.

Radiographic Findings Associated with Carcinoid Fibrosis
The distinctive radiographic findings associated with carcinoid tumors and fibrosis
have been described in several series. In a retrospective analysis of computerized tomography
(CT) findings in 29 cases of proven mesenteric carcinoid tumors, findings were analyzed
with matching histological sections to correlate independently for histological pattern, degree
137

of fibrosis, and calcification within the mass . All calcification was localized within areas of
sparsely cellular mature fibrous tissue and the degree of radiating strands detected by CT
138

tended to increase with the degree of fibrosis seen histopathologically . Mesenteric lymph
node metastases were evident at surgery or on CT scans in 286 patients (91%) in one
104

series . On abdominal films, mesenteric fibrosis may lead to traction or fixation of the
139

bowel . Angiographic changes are more distinctive, with narrowing or occlusion of the
139,140

distal ileal arcade and stenosis of the intra-mesenteric arteries characteristic findings

.

Management of Carcinoid Fibrosis
Treatment of patients with midgut carcinoids and their associated fibrosis has been
limited mostly to surgery, providing therapeutic and palliative relief to patients and resulting
in favorable long-term survival rates. The 5-year survival rate for all patients with operable
tumors was 68% in Moertel’s series, while only 38% of patients with inoperable metastases
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survived five years or more after diagnosis . Among the 59 patients in Makridis’ series found
to have mesenteric fibrosis at laparotomy, 78% remained free of preoperative symptoms
98

during a mean 4.2 years of follow-up . In Hellman’s series, 68.7% of patients demonstrated
a reduction in symptoms (e.g. diarrhea, abdominal pain) and improved survival after surgical
104

intervention . In a series of 31 patients with metastatic carcinoid disease, resection of liver
metastases prolonged survival and reliably eliminated the incapacitating symptoms of the
141

tumors (i.e. carcinoid syndrome) . More recent data have noted that while the presence of
liver metastases at presentation did not appear to influence survival, patients with
symptomatic tumors exhibited a 5-year disease-free survival of 46% compared to 72% in
142

asymptomatic patients . This however may simply be a reflection of tumor burden and
indicative that the metastatic load per se correlates with prognosis.
Intestinal stricture (stenosis) consequent upon superior mesenteric vein (SMV)
thrombosis is a relatively infrequent, though important, cause of intestinal obstruction. In
general, there is some evidence that immediate anti-coagulant therapy is useful in treating
143

patients with SMV thrombosis (of various etiologies) . However, most carcinoid studies to
92,104

date have utilized a surgical approach in attempting to treat this phenomenon

. No

prospective studies examining other interventional modalities such as vein grafting or bowel
auto-transplantation are currently available.

Biological Basis of Fibrosis
Fibrosis is usually a normal component of tissue repair and represents a dynamic and
interrelated process comprising angiogenesis, tissue remodeling, inflammation and fibroblast
144

contraction . A proper balance between synthesis and degradation of extracellular matrix
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molecules (e.g. collagen) is also of critical importance for the outcome of this process. After
initial injury, cytokines are generated, which are important in the functional restoration of
damaged tissue. Prolonged production of these cytokines, however, can lead to excessive
matrix accumulation and chronic fibrosis (Figures 15 and 16). The consequences of such
fibrosis, as found in desmoplastic lesions and in association with some tumors, represent a
neoplastic manifestation of disordered repair and are often associated with serious clinical
sequelae such as obstruction, ischemia, and disfigurement. Carcinoid fibrosis is as such an
unregulated, fibrotic neoplastic process for which the biological basis has not been defined.

Carcinoid Fibrosis-Related Factors
A number of different factors potentially involved in small bowel carcinoid fibrosis
have been examined. The focus has largely revolved around the secretory products of the
small bowel-derived enterochromaffin (EC) cell.

Serotonin
The relationship between serotonin and small bowel fibrosis is not well characterized
and data regarding its role are often inconsistent. In 1994, Moertel hypothesized based on
145

his clinical data that serotonin may play a vasoconstrictive role in ischemia . Methysergide
and ergotamine are serotonin antagonists that are used in the treatment of migraine
146

headaches and an uncommon side-effect of their usage is retroperitoneal fibrosis . It was
initially thought that these anti-serotonergic agents may cause fibrosis by interacting with
147

serotonin receptors in some “unknown” fashion . This was a surprising concept given the
hypothesis that serotonin itself stimulated fibrosis presumeably via activation of a serotonin
receptor. The specificity or validity of this observation, however, appears to be low given the
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Figure 15: A proper balance between synthesis and degradation of extracellular matrix molecules (collagen)
after cellular injury characterizes the normal wound healing process.

Figure 16: Fibrosis is usually a normal component of tissue repair and represents a dynamic and interrelated
process comprising angiogenesis, tissue remodeling, inflammation and fibroblast contraction. When this
process goes awry, it can lead to excessive production and deposition of collagen and chronic fibrosis. Although
fibrotic disorders can be acute or chronic, the disorders share a common characteristic of excessive collagen
accumulation and an associated loss of function when normal tissue is replaced with scar tissue.

fact that other serotonin antagonists that interact with the same receptor (e.g. cyproheptadine
and pizotifen, both of which are used to treat migraines) are not associated with fibroblastic
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responses . It is more likely that the antagonist, by interacting with a low-affinity (nonspecific) serotonin receptor, may ameliorate or incite an inhibitory effect on fibrosis.
Whatever the mechanism, the finding that a serotonin antagonist causes fibrosis
strongly supports that other factors are important in this process and that the implication of
serotonin itself is likely to be an upstream event or a correlatable epiphenomenon given its
secretion by the EC cell. More substantial evidence, however, exists for serotonin as an
etiologic agent in the development of carcinoid heart disease. Several studies have
demonstrated that patients with carcinoid tumors, those with cardiac involvement have
149-153

higher levels of 5-HIAA, than patients without cardiac involvement
90

One recent study

.

has demonstrated a close relationship between serotonin and

cardiac disease. Support for a role for serotonin in valvulopathy has been described after
154

prolonged administration of the diet drug combination of flenfluramine-phentermine . Of
note, the anti-migraine drug methysergide (associated with retroperitoneal fibrosis) is also
146

associated with heart valve fibrosis , suggesting that a similar process may occur in this
tissue. Because methysergide cannot be considered a selective antagonist, other explanations
including concomitant adrenergic blockade, CNS-mediated hypotensive effects, and even a
partial agonist activity have been proposed to explain this fibrogenic effect. Serotonin,
155

however, itself is mitogenic to fibroblasts in culture , but only under circumstances where
156,157

such cells have been transfected with the appropriate receptor

. Attempts to induce

cardiac lesions of the carcinoid syndrome by chronically injecting pharmacological amounts
158

of serotonin in animals have been unsuccessful . The concept that serotonin plays a role in
fibrosis is therefore not based on conclusive evidence and definitive studies have yet to be
performed. It appears most likely, given the balance of data and the clinical observations with

52
respect to the retroperitoneum, that while an absolute increase in serotonin appears to be
significant in relationship to the development of fibrosis, this may represent a correlatable
epiphenomenon. It is more likely that secreted factors other than this agent play important
roles in the development of fibrotic lesions.

Tachykinins
The role of tachykinins in fibrosis may be important, as members of this family (e.g.
159

neurokinin A, substance P) have been demonstrated to stimulate fibroblast growth , and the
3

same tachykinins are known to be secreted in a majority of patients with midgut carcinoids .
Very little, however, is known about these mediators and their relationship to carcinoid
fibrosis, as there is a paucity of studies investigating this subject.

Growth Factors
In the last two decades, focus shifted from serotonin to growth factors as the etiologic
agents of carcinoid-related fibrosis. Growth factors represent a heterogeneous group of
polypeptides that act locally and stimulate cell proliferation and differentiation by binding to
160,161

specific high-affinity cell membrane receptors

. Such polypeptides stimulate cell

proliferation by diffusing short range through intracellular spaces and acting locally, contrary
to the more distant endocrine action of hormones. Expressed in various mammalian cells and
tissues, growth factors have been noted to play an increasingly significant role in
development, wound healing, and carcinogenesis. Recognition of the mitogenic properties of
growth factors on fibroblasts became evident and a putative role for their involvement in
carcinoid tumor growth became apparent. Candidates included platelet-derived growth factor
(PDGF), insulin-like growth factors I and II (IGF-I and -II), epidermal growth factor (EGF),
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and the tissue growth factor-alpha and -beta (TGF-α and TGF-β) families of peptides, all of
162

which have been demonstrated in malignant cells . Proliferation and differentiation of cells
in normal tissues is tightly controlled by several growth factors, and perturbations to this
160

process may lead to uncontrolled growth and tumor formation .

PDGF
PDGF may play a role in connective tissue cell proliferation during chronic
inflammation. The PDGF-β receptor, not typically expressed on resting cells in normal
tissues, has been reported to be induced on connective tissue cells in chronic inflammatory
163

conditions such as rheumatoid arthritis and rejected kidney transplants .

Chaudhry

demonstrated that fibroblasts in carcinoid tumors express multiple PDGF receptors,
164

suggesting that they respond to any of the three dimeric forms of PDGF . Interestingly, the
surrounding stromal component of these tumors synthesizes PDGF-α and -β chains, which
164

may stimulate the growth of carcinoid tumor cells in a paracrine manner . In a series of 31
midgut carcinoid tumors, the PDGF-β receptor was demonstrated by immunohistochemical
staining in 66% of tumors (compared to only 9% of non-neuroendocrine tumors staining
positively for the same receptor), and the stromal cells adjacent to the tumor cells stained
163

more strongly than stromal cells that were distant from tumor clusters . This suggests that
carcinoid tumor cells may directly or indirectly induce expression of the PDGF-β receptor on
adjacent stromal cells in the tumor tissue, which may possibly contribute to the stimulation of
163

connective tissue cell proliferation in carcinoid tumors .

IGF-I
IGF-I, structurally homologous with proinsulin and biologically similar to insulin, plays an
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important role in the physiological regulation of cell growth and differentiation . The
mitogenic effects of IGF are mediated via the IGF-I and -II receptors. Nilsson and his
colleagues demonstrated the presence of the IGF-I receptor in 11 consecutive cases of midgut
carcinoid tumors, suggesting that it may possibly act as an autocrine stimulator of carcinoid
162

tumor growth .

EGF and TGF-α
Epidermal growth factor (EGF), in addition to the TGF-α and -β families of growth
166

peptides, can stimulate or inhibit proliferation and differentiation in multiple tissues .
TGF-α, a peptide structurally related to epidermal growth factor (EGF), is expressed in
abnormally high quantities in tumor cells and mediates its effects by binding to the EGF
receptor . In a series of 18 midgut carcinoid tumors, TGF-α and the EGF receptor were
162

expressed in every specimen, suggesting that TGF-α participates in the autocrine modulation
162

of carcinoid growth .

TGF-β
The TGF-β family of growth factors, neither structurally nor functionally related to
TGF-α, exists in three isoforms (β1, β2, β3) in mammalian cells and tissues and acts as a
potent autocrine growth-inhibitory factor in normal cells

160,167

. TGF-β has been found in

most fibrotic lesions and is considered to be a critical profibrotic mediator due to its known
168

ability to stimulate collagen synthesis . TGFβ1 and the receptor subtype-2 (TGFβrII) have
169,170

been identified in midgut tumor samples

. Similarly it has been demonstrated that tumor
171

cells from carcinoids express TGFβ1 while stromal cells express the TGF-βII receptor . This
suggests that TGFβ1 may play an important role in the interaction between tumor and
172

stromal cells. In a study that examined patients undergoing valve replacement surgery ,
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TGF-β was detected in the fibroblasts of all analyzed heart plaques. This supports the
concept of an induction of TGF-β during the development of the fibroproliferative lesions in
carcinoid heart disease. While one study demonstrated that serotonin may up-regulate TGFβ1 in aortic valve interstitial cells , a second study in a small number of patients found no
173

151

relationship between circulating levels of TGF-β and carcinoid heart disease . Despite this
latter finding, a current hypothesis is that serotonin may regulate TGF-β-mediated fibrosis in
173

this disease process .
A summary of the proposed biological mechanisms of the growth factors associated
with carcinoid tumor growth is illustrated in Figure 17.

Connective Tissue Growth Factor
Recent studies have investigated the role of connective tissue growth factor (CTGF),
a novel, cysteine-rich peptide involved in the coordination of complex biologic processes such
174

as differentiation and tissue repair . CTGF is the prototypic member of the CCN family of
proteins

175,176

, which are 30–40 kDa cysteine-rich proteins (Figure 18). Discovered in the

early 1990’s, these proteins stimulate mitosis, adhesion, apoptosis, extracellular matrix
(ECM) production, growth arrest and migration. CTGF has been detected in fibroblasts,
cartilaginous cells and chondrocytes, cancer cell lines, smooth muscle cells, renal podocytes
and mesangial cells, hepatic sinusoidal cells, myofibroblasts, pancreatic acinar and ductile
177

cells, bronchoalveolar ductile cells, as well as in serum, tear fluid, and urine . CTGF
participates in several physiological processes, including embryonic development and
178

differentiation, endochondral ossification, wound healing, and angiogenesis . Depending on
the cell type, CTGF has been noted to promote mitosis, chemotaxis, stimulate apoptosis,
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Figure 17: Proposed mechanism of the potential effects of small bowel carcinoid tumor-derived CTGF on local
(retroperitoneal) and distant (cardiac) fibrosis. TGFβ1 auto-activates CTGF mRNA synthesis and protein release
from the small bowel carcinoid tumor cells. Secreted CTGF and TGFβ1 interact locally with stromal cells,
inducing collagen synthesis and deposition (and the resultant fibrosis in 42-78% of patients) in the
retroperitoneum. CTGF also enters the bloodstream and may potentially act distantly in the heart via activation of
cardiac fibroblasts with collagen deposition and the consequent endocardial fibrosis, valvular fibrosis, and rightsided heart failure (noted in 20-38% of patients).

angiogenesis, synthesis of collagens, fibronectin and α5-integrin . The low density
179

lipoprotein (LDL) receptor-related protein/α-2-macroglobulin receptor (LRP2) has been
180

demonstrated to be the receptor for CTGF in fibroblasts . By signaling via integrins, a
mechanistic interpretation is provided for the chemotactic and mitogenic properties of CTGF,
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as well as for its functions in ECM
remodeling during angiogenesis and
177

wound healing .
Several factors are capable of
regulating CTGF gene expression,
although it is generally believed that
CTGF is transcriptionally activated

Figure 18: Schematic representation of the CCN family of

primarily

In

matricellular proteins that have been grouped together based on
a similar predicted structure. CTGF (CCN2) plays an

addition to TGFβ1, CTGF gene

essential role in the formation of blood vessels, bone, and
connective tissue.

through

TGFβ1.

expression is also influenced by
elevated glucose levels, tumor necrosis factor-α (TNF-α), vascular endothelial growth factor
(VEGF), cortisol, cAMP, coagulation protease thrombin, prostaglandin E2 (PGE2), drugs
181-189

such as iloprost and statins, as well as with cytomegalovirus infection

. Of particular

relevance, however, are recent reports that describe how other growth factors, including
platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and fibroblast
178,190

growth factor (FGF), activate CTGF gene expression at a transcriptional level

.

The intracellular pathways regulating CTGF are still not clear. Recently, Leask and
his colleagues reported that SMAD, PKC and ras/MEK/ERK (kinase) pathways are necessary
191

for the TGFβ1-mediated induction of the CTGF promoter . As a mediator of fibrosis, the
expression of CTGF has been noted to increase in several pathological conditions involving
inflammation and connective tissue accumulation. The expression of CTGF has been
reported to be practically absent in normal human arteries, but highly enhanced in the intimal
192

smooth muscle cells of atherosclerotic lesions and in myocardial infarctions . In the human
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kidney, the expression of CTGF has been found to be markedly increased in glomerular and
interstitial inflammatory lesions with cellular proliferation and matrix accumulation (e.g. IgA
nephropathy,

chronic

transplant

rejection,

crescentic

glomerulonephritis,

focal
193

glomerulosclerosis, lupus nephritis and membranoproliferative glomerulonephritis) .
Furthermore, the up-regulation of CTGF has been noted in numerous other pathological
conditions, including scleroderma, keloid formation, malignant melanoma, chronic
pancreatitis, hepatitis and liver cirrhosis, Crohn’s disease, ulcerative colitis, pulmonary
179

fibrosis, and sarcoidosis .
174

CTGF mediates normal scar formation in wound healing . Physiologically, the
activity of TGFβ1 and CTGF diminishes as the wound heals and adequate scar formation is
177

achieved . However, in pathological diseases where the inflammatory component remains,
177

the expression of CTGF stays elevated with a concomitant elevation in ECM production .
The chronic induction of the CTGF expression results in a pathologic fibrosis of the involved
177

organ and development of abnormal fibrotic tissue .
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HYPOTHESIS

CTGF is a substantial candidate for consideration as the local and circulating
regulator of small bowel carcinoid fibrosis. I hypothesize that the ill-understood and
dangerous phenomenon of fibrosis associated with small bowel carcinoids is specifically due
to a secreted tumor factor derived from the EC cell, namely CTGF. The overall aims of this
study are to address whether CTGF is over-expressed and secreted by small bowel EC
carcinoid tumors, determine if there exists a relationship between CTGF and small bowel
carcinoid fibrosis, and if so, what role this growth factor plays in the genesis of ileal
carcinoid-related fibrosis and whether measuring serum levels of CTGF has any clinical
utility in the identification of patients with carcinoid tumors and/or fibrosis. Schematic
models of this hypothesis (Figures 19 and 20) illustrate the proposed profibrotic effects of
CTGF in patients with carcinoid tumors.
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Figure 19: Proposed mechanism of the potential effects of small bowel carcinoid tumor-derived CTGF on local
(retroperitoneal) and distant (cardiac) fibrosis. TGFβ1 auto-activates CTGF mRNA synthesis and protein release from the
small bowel carcinoid tumor cells. Secreted CTGF and TGFβ1 interact locally with stromal cells, inducing collagen synthesis
and deposition (and the resultant fibrosis in 42-78% of patients) in the retroperitoneum. CTGF also enters the bloodstream
and may potentially act distantly in the heart via activation of cardiac fibroblasts with collagen deposition and the consequent
endocardial fibrosis, valvular fibrosis, and right-sided heart failure (noted in 20-38% of patients).
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Figure 20: Schematic representation of the proposed biological mechanisms responsible for carcinoid-related fibrosis.
TGFβ 1, released by both carcinoid tumor and stromal cells, interacts with the TGFβ receptor subtype-2 on the tumor
cell, whereby its activation results in CTGF mRNA synthesis and protein release from the tumor. CTGF and TGFβ1
have been shown to be secreted in excess from EC carcinoid tumor cells. Once secreted, both TGFβ1 and CTGF interact
with the stromal cells, inducing collagen synthesis and deposition (and the resultant fibrosis).
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STUDY DESIGN AND METHODS*

SPECIFIC AIM #1: Examine sera and tissue samples using standard
assays to identify whether CTGF is over-expressed and/or
secreted by small bowel carcinoids.
Serum and Tissue Sample Acquisition

Patient Recruitment: The P.I. (Dr. Irvin Modlin) is responsible for a neuroendocrine
referral center at Yale University in consultation with Dr. John Murren and sees an
average of 2–3 new patients with carcinoid disease on a weekly basis. I prospectively acquired
sera from patients attending this clinic. A second patient resource is the Yale Surgical
Oncology Group that examines patients with EC carcinoids or their liver metastases who are
operated on each year, and there is a subset of these patients (7-10) who have carcinoid heart
disease and are regularly examined.

Additionally, a retrospective databank of 23 serum

samples had been collected previously from patients attending the aforementioned clinics.
These samples included 20 patients with GI carcinoids: small bowel EC carcinoids (n=10),
gastric ECL cell carcinoids (n=4); and six other GI carcinoids (rectal: n=2, parotid: n=1,
appendiceal: n=2, duodenal: n=1). Serum samples from three patients undergoing hernia
repair were also collected.

Tumor tissue from nineteen patients with gastrointestinal

carcinoids (EC, n = 16; ECL, n = 3) as well as tissue from nine adjacent, unaffected areas had
previously been collected as well. It was estimated that approximately 60 patients would be
recruited per year from the following groups attending these clinics:
1. patients with small bowel carcinoids
2. patients with gastric carcinoids
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3. patients with other diseases requiring surgery (e.g. ulcerative colitis, colorectal
cancer, hernia repair)
4. normal subjects
4

Based on previous studies that demonstrate fibrotic complications in 16-48% of patients , I
estimated that a minimum of 10 patients from the small bowel tumor group would have or
develop fibrotic complications.
The recruitment and consenting of research subjects in this particular study was
approved by the Human Investigations Committee at the Yale University School of Medicine
(HIC #12589). Patients were required to sign an informed consent form that provided a
brief description of the research project, the procedures used, risks and inconveniences,
benefits, and economic considerations. All participants were informed of the voluntary nature
of their participation and assured of the strict maintenance of confidentiality. Participants had
the opportunity to ask any questions and were offered a copy of the information sheet for
their records, which included contact information of the principle investigator. Upon signing
and dating the consent form, blood samples were collected immediately.
Epidemiological characteristics were recorded for each patient, including age, sex,
diagnosis, surgical history, radiological studies (particularly Octreoscan), pertinent
medications related to their carcinoid disease (e.g. octreotide), and current therapeutic
management of their carcinoid disease. A current or previous history of carcinoid syndrome
was assessed by asking patients whether they have experienced several consecutive days of
frequent episodes (>3/day) of diarrhea or facial flushing.

Tissue Collection
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Our laboratory has established a frozen-tissue databank of tumors including
enterochromaffin cell (EC) and enterochromaffin cell-like (ECL) carcinoids of the ileum and
stomach, pancreatic gastrinomas, and adenocarcinomas of other gastrointestinal sites, as well
as normal tissue sampled from sites adjacent to these tumors. This databank was augmented
by tissue samples I collected prospectively during the experiment period.
As part of our approved HIC protocols (#12589 and #11041), I collected tissue
samples in the operating rooms at Yale–New Haven Hospital from patients undergoing
surgical resection of carcinoid tumors. As with the serum collection, informed patient consent
was obtained pre-operatively for the collection and use tissue samples. In patients undergoing
bowel resection or gastrectomy, tumor tissue was collected and paired with adjacent, normal
mucosa. Each tissue sample was stored immediately in a -80°C freezer until needed.

Examination of CTGF Expression in Carcinoid and Normal Adjacent Tissues
The following RNA isolation and RT-PCR experiments were performed by Dr. Mark Kidd.
RNA Isolation: Total RNA was isolated from frozen carcinoid tumor tissue (n=19) and
normal mucosa (n=9) using TRIzol reagent (Invitrogen, Carlsbad, CA) using the
manufacturer’s

guidelines.

RNA

was

dissolved

in

DEPC

water,

measured

spectrophotometrically and an aliquot analyzed on a denaturing gel using electrophoresis to
check the quality of RNA isolated.
RT-PCR: 19 tumor samples and 9 normal mucosal samples were examined by RT-PCR. 2
μg of total RNA underwent cDNA synthesis using SUPERSCRIPT Reverse Transcription
(Invitrogen). For semi-quantitative PCR, GAPDH was used as a “house-keeping” gene
(primers: Forward 5’-GTG AAG GTC GGA GTC AAC, Reverse 5’-GGT GAA GAC GCC
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AGT GGA CTC). Thereafter, PCR was undertaken with each sample for CTGF (primers:
Forward 5’-GAG GAA AAC ATT AAG AAG GGC AAA, Reverse 5’-CGG GAC AGG TCT
194

TGA TGA) , and imaging densitometry undertaken (NIH Image 1.6, NIH, Bethesda) of
195

the ethidium bromide gels to quantify the gene product.

Quantitative RT-PCR Analysis of CTGF and TGFβ1 mRNA Expression in Small Bowel and
Gastric Carcinoid Tumors
RNA samples were quantitatively measured for TGFβ1, TGFβRI, TGFβRII and
p21

(WAF/CIP1)

196

message by Q-PCR as described . Briefly, Q RT-PCR (was performed using the

ABI 7900 Sequence Detection System. Total RNA from each sample was subjected to reverse
transcription using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA) following the manufacturers suggestions. Total RNA (2 μg/50 μl) was reversetranscribed and real time PCR analysis was performed in duplicate on these samples. Briefly,
cDNA in 7.2 μl of water was mixed with 0.8 μl of 20x Assays on Demand primer (TGFβ1=
Hs00171257,

TGFβRI=Hs00610319,

TGF-βRII=Hs00559661,

p21

(WAF/CIP1)

=

Hs00355782, GAPDH=Hs99999905) and probe mix, 8 μl of 2x TaqMan Universal PCR
Master mix in a 384 well optical reaction plate. The following PCR conditions were used:
50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C/0.15 min and 60°C /1
min. A standard curve was generated for each gene using cDNA obtained by pooling equal
amounts from each sample (n=12). The expression level of target genes was normalized to
internal GAPDH. Data was analyzed using Microsoft Excel and calculated using the relative
standard curve method (ABI, User Bulletin #2).
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SPECIFIC AIM #2: Determine if there exists a relationship
between CTGF and small bowel carcinoid fibrosis by genetically
and proteomically defining the small bowel tumor fibrosis
phenotype as opposed to the non-fibrogenic gastric carcinoid
tumor and correlate this information with clinical outcomes
for each patient.
Clinical Relevance of Proteomics and Tissue Microarrays (TMA)
Detailed analysis of gene expression in both prokaryotes and eukaryotes using DNA
microarray technology allows for parallel analyses of the expression of thousands of genes to
197

address complex biological questions . This is important because the properties of cancer
cells can vary enormously from one patient to another; as such, it is often not possible to
characterize individual tumors by means of a single, or even several, molecular markers. The
properties of cancer cells reflect the functions of all their gene products. Presumably this is
true for fibrosis as well. The clinical use of gene expression profiles has the potential of
offering more accurate and objective diagnoses of cancers as well as prognoses of a disease or
response to treatment.
GeneChip® microarray studies have provided a broad and efficient approach toward
198

identifying such candidate markers and drug targets . Gene expression analyses do not,
however, provide reliable information on the actual proteins encoded by genes showing
altered expression, because there is often no direct relationship between in vivo concentration
of an mRNA and its encoded protein. Differential rates of translation of mRNAs into protein
and differential rates of protein degradation in vivo are two factors that confound the
199

extrapolation of mRNA to protein expression profiles . While DNA arrays allow expression
analysis of thousands of genes in a single specimen, the recently developed methods of
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proteomics and tissue microarrays (TMA) provides a means to examine the protein
expression of the genes.
Proteomics, or peptide profiling, is a relatively new field that has begun to show
promise in the diagnosis, early detection and the monitoring of prognosis in many different
200

diseases . Differential two-dimensional fluorescence gel electrophoresis (DIGE) utilizes in

vitro labeling with Cy3/Cy5 fluorophores, can detect a number of post-translational
modifications, has an approximate dynamic range of 10,000; quantifies approximately
1,000 spots; and is optimized for naturally-occurring forms of proteins larger than 10
201

kDa . This method is well-suited for the identification of proteins in specimens.
202

Proteomics has emerged as a useful tool for studying connective tissue biology . In
this study, we used this approach to determine the protein profiles of small bowel carcinoid
203

tumors. TMA permits rapid molecular profiling of hundreds of pathological specimens

(high through-put analysis) and is therefore also suited for analyses of candidate proteins
identified in gene expression and microarray experiments

197,204

. Formalin-fixed archival

tissues provide a means to validate targeted gene-protein identification and genomic
screening in large sets of histologically well-characterized samples with clinical endpoints.
To get a fuller picture of the complexity of processes and pathways involved in the
pathophysiology of small bowel carcinoid fibrosis, efficient protein profiling and TMA
immunohistochemistry is necessary to compliment the RNA analyses and provides additional
insight into how genes act and interact at the protein level. We have begun to use a
combination of gene, protein and TMA analysis in small bowel carcinoids, and this triple
approach is being used to identify how fibrosis is generated and for the identification of small
bowel fibrotic mediators.
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Carcinoid Tumor TMA: Design and Applications
With assistance from Dr. Robert Camp of the Yale University Department of
Pathology Tissue Microarray Facility, a carcinoid tissue microarray was constructed from
banked pathology specimen blocks. This microarray (YTMA#32; the only such carcinoidspecific array in the United States) includes thirty-six patients identified at Yale University
over the last twenty-four years with carcinoids of the small bowel (no fibrosis: n=21;
fibrosis: n=15), 7 patients with gastric carcinoids, normal liver and normal bowel tissue. A
second array (YTMA#60) is presently being constructed with the tissue samples I obtained
over the course of this study, which includes fibrotic, metastatic, normal mucosa and cardiac
tissue. Currently, our collection includes 55 small bowel carcinoids, 12 gastric carcinoids,
metastatic tissue in the lymph nodes (n=14), metastatic tissue in the liver (n=10), normal
adjacent mucosa from every tumor (n=67), and fibrosis (n=28) from small bowel carcinoids.
The tissue microarray is a novel method of harvesting small cylinders of tissue from
standard histological sections and placing them in a well-defined matrix in a recipient
paraffin block

205

(Figure 21). Sections are then made of this multi-sample block and affixed

to standard glass microscopy slides, which can then be used for simultaneous in situ analysis
of primary tumors, material of interest
(e.g. areas of fibrosis), or non-affected
tissue at a protein level.

The large

number of tissue samples on a single
slide

can

be

simultaneously

immunostained using this technique,

Figure 21: Example of a tissue microarray. With this technique,
hundreds of tissue samples can be studied simultaneously.
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and a variety of clinical parameters
(e.g.

presence

or

absence

of

fibrosis, dissemination of disease,
patient

survival

characteristics,

operative course) can then be
correlated with these results in a
206

single experiment (Figure 22) .

Figure 22: H&E stain of the carcinoid tissue microarray showing
two tumor sections on the grid (100x magnification).

Construction and Processing of GI Carcinoid TMA
Formalin-fixed paraffin-embedded tissue blocks containing GI carcinoids (stomach:

n=7; duodenum: n=5; small bowel: n=36; appendix: n=20; colon: n=7) were retrieved,
along with the corresponding H&E-stained slides, from the archives of the Yale University
School of Medicine Department of Pathology prior to the start of this project. Blocks were
stored under ambient conditions within a temperature range of 18-37°C. To ensure
uniformity of sectioning, older paraffin blocks were melted and re-embedded using
modern-day plastic cassettes. Tumors were staged and histologically typed according to the
recommendations of the pathologist (Dr. Robert Camp). Normal and areas of fibrosis were
appropriately identified. A full-time lab technician constructed the TMA by taking core tissue
biopsies 0.6 mm in diameter from carefully selected morphologically representative regions
of individual paraffin-embedded tumors, and/or adjacent fibrosis and/or normal mucosa and
precisely arrayed into a new recipient paraffin block (45 mm x 20 mm) using a custom-built
instrument. Sections of the resulting tissue microarray block 5 μm thick are then transferred
to glass slides by the technician using the paraffin sectioning aid system (adhesive coated
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slides PSA-CS4x, adhesive tape, UV lamp, Instrumedics Inc., Hackensack, NJ) to support the
cohesion of 0.6-mm array elements. Immunohistochemical analysis could then be performed
on proteins of interest (e.g. CTGF).
Two separate tissue microarrays were used in this study. The first array contained
10 cases and was used to titrate antibodies and establish the efficacy of the array. The
seconds array contained 75 cases of primary GI carcinoids diagnosed between 1965 and
2001 and was represented by 2 cores per case. Follow-up information was available
(median follow-up: 9 years, range: 2-38 years) for all patients. This microarray includes
thirty-six patients with carcinoids of the small bowel in whom the fibrotic and
metastatic/malignant-associated clinical details were known.

Immunohistochemical Staining of TMA
206

Tissue microarray slides were stained as described by Dr. Camp and his colleagues .
In brief, for automated analysis, slides are incubated for 1 hr at room temperature with
mono- or polyclonal antibodies (1:200-1:1,000; Santa Cruz Biotechnology Inc, CA or
DAKO Corp, Carpinteria, CA, or Zymed Laboratories, San Francisco, CA) diluted in Trisbuffered saline containing BSA. Secondary antibodies conjugated to a horseradish
peroxidase-decorated dextran polymer backbone (Envision; DAKO Corp) were used. For
automated analysis, tumor cells were identified by the use of a fluorescently tagged
anticytokeratin antibody cocktail (AE1/AE3; DAKO Corp), after which 4’,6-diamidino-2phenylindole was added to visualize nuclei, and proteins of interest were then visualized with
a fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston, MA). Cy-5
(red) was used because its emission peak is well outside the green-orange spectrum of tissue
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autofluorescence. Protein expression was determined using an automated tissue microarray
reader controlled by Dr. Camp.
Automated image acquisition and analysis using AQUA has been described previously
206

by Dr. Camp and his colleagues as well . In brief, monochromatic, high-resolution (1024 x
1024 pixel; 0.5-μm) images are obtained of each histospot. Areas of tumor can be
distinguished from stromal elements by creating a mask from the cytokeratin signal.
Coalescence of cytokeratin at the cell surface helps to localize the cell membranes, and 4’,6diamidino-2-phenylindole is used to identify nuclei as mentioned above. The red Cy-5 signal
from the membrane area of tumor cells is scored on a scale of 0–255 and expressed as signal
intensity divided by the membrane area. Histospots containing <10% tumor, as assessed by
mask area (automated), are excluded from further analysis. Previous studies have
demonstrated that the staining from a single histospot provides a sufficiently representative
207

sample for analysis . Previous data have also demonstrated that mean alterations in AQUA
scores of 7 (in a range of 0-255) are sufficiently sensitive to discriminate protein expression
206

and provide statistically significant data . In addition, a minimum number of samples
204

(n=10) is required for statistical significance .
Dr. Kidd and I deparaffinized consecutive sections of the TMA or normal small
bowel mucosa in xylenes and rehydrated them in graded alcohols. Antigen retrieval and
immunostaining was performed as described above. Serial sections (5 μm) were incubated
with goat antiserum to CTGF (1:250) and a monoclonal antibody against CgA (0.5 μg/ml)
or serotonin (2 μl/ml) (both from DAKO) for 24 hr at 4°C and then with FITC-labeled antirabbit and TRITC-labeled anti-goat IgG (1:200 dilution) for 1 hr at RT. HRP-amplification
was performed as above and bound antibodies visualized under light microscopy. Single-
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positive (either serotonin or CgA) and dual-positive cells (CTGF + serotonin or CTGF +
CgA) were counted in a minimum of 5 well-orientated crypts and expressed as a percentage.
The unpaired 2-tailed Student’s t-test was used to identify statistically significant
differences in fibrotic protein expression between different patient groups (fibrosis versus
non-fibrosis, fibrosis versus gastric carcinoid). The significance was set to p<0.05. The χ 2

test (Fisher’s exact text) was used to evaluate the statistical significance (presence or absence
of staining) in any two groups.

SPECIFIC AIM #3: Determine whether measuring serum levels of
CTGF has any clinical utility in identifying patients with
fibrosis.
Serum Collection
After obtaining consent from the patient, I collected 10 ml of peripheral venous blood
using a 21-gauge Vacutainer Safety-Lok Blood Collection Set (Becton Dickinson, Franklin
Lakes, NJ) into two 6 ml lithium heparinized plastic Vacutainer tubes (Becton Dickinson,
Franklin Lakes, NJ). The samples were then centrifuged for five minutes at 1000g within
thirty minutes of collection. The serum was aliquoted into 1.8 ml Nunc cryotubes (Nunc
A/S, Roskilde, Denmark) and stored at -20° C until needed for various analytical assays.
Prior to analysis, the frozen samples were left to stand at room temperature to thaw,
and then inverted several times to mix. The plasma aliquots from all temperature and timepoints for each volunteer were analyzed together in one batch, to avoid run-to-run variability.

Serum Analysis
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The first objective was to identify the serum secretory profile of CTGF secretion in
carcinoid tumors. Because TGFβ1 is an upstream regulator of CTGF, this was measured as
well, along with Chromogranin A and serotonin. Chromogranin A was used as a marker of
tumor mass, and serotonin was examined because it has been identified as a marker for
90

carcinoid heart disease . Each serum sample was analyzed for these four proteins. Fasting
samples were obtained to obviate any exogenous humoral release.

Serum CTGF levels
Based on our preliminary data (mean serum CTGF levels = 23 ng/mL in carcinoid
patients vs. 12 ng/mL in patients with other tumors) and using a 99.5% significance level (p
< 0.005 that the hypothesis is true due to chance alone), and a power of 1.0, the numbers of
serum samples from patients to be prospectively examined for CTGF levels was calculated to
be 15. The sera of a subgroup of these patients was examined serially to verify the inter- and
intra-test reproducibility of the assay and to examine whether the serum levels of CTGF are
constant or fluctuate as a function of time or surgical removal of a carcinoid tumor.
Temporal expression of serum CTGF as well as the effects of surgery on CTGF levels
in a number of different groups of patients (hernia repair and tumor resections) was
examined by measuring pre-operative baseline serum CTGF followed by another serum
measurement 24 hour postoperatively.

Potential Confounders:
1) Pharmacotherapeutics: Because it was unknown whether Sandostatin® (a somatostatin
208

analogue used in the treatment of carcinoid symptoms)

might affect either TGFβ1 or
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CTGF secretion, it was treated as a potentially confounding variable. I therefore examined
fasting serum levels in new patients to the clinic (who were not on the drug) and later during
the course of their treatment at 3 monthly intervals (if and/or when they have begun
treatment of this drug). For patients who were taking the long-acting regimen (LAR), serum
was obtained immediately prior to their next injection. For patients who were injected with
the short-acting somatostatin analogue, octreotide (which has a half-life of 8 hr), a 72 hr
injection-free period was followed prior to serum acquisition.

2) Surgery: when serum samples were needed from patients undergoing hepatic
embolization or surgical resection, I collected the samples immediately before the procedure.

CTGF Serum ELISA
Serum CTGF-W (whole molecule) and CTGF–N (N-terminal fragment) was
measured by Dr. William Usinger of Fibrogen (at their lab facilities in San Francisco, CA) by
sandwich enzyme-linked immunosorbent assay (ELISA) using two non-cross blocking
proprietary monoclonal antibodies reacting to distinct NH2-terminal epitopes of CTGF as
209

described . In brief, ELISA plates (Immulon 2) were coated overnight with a monoclonal
antibody directed to the amino terminus of CTGF. Wells were washed and blocked with
buffer containing BSA and then rinsed. Another amino-terminal anti-CTGF monoclonal
antibody solution (50 μl) conjugated to biotin was added. Then 50 μl (in duplicate wells) of
each standard, control, or serum sample, pre-diluted in assay buffer, was then added to the
plate, covered, and incubated at 4°C on a plate shaker for 1.5 h. The plate was washed three
times with wash buffer, and 50 μl of a solution of streptavidin conjugated to alkaline
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phosphatase was added to each well. The plate was again covered and incubated at 4°C on a
plate shaker for 1.5 h. The plate was washed three times with wash buffer. Then 100 μl of
substrate buffer containing para-nitrophenyl phosphate was added to each well. After proper
color development, the enzyme activity was stopped by the addition of 50 μl of 4 N NaOH.
The plate was read at 405 nm, and data was fitted using a quadratic fit option. Standards
were made from purified full-length CTGF and expressed in nanograms per milliliter. The
described CTGF ELISA is capable of detecting both full-length CTGF (CTGF-W) as well as
an amino-terminal fragment of CTGF. The intra- and interassay co-efficient of variations are
5 and 15%, respectively.

TGFβ1 serum ELISA
This assay, performed under the guidance of Dr. Kidd, employed the quantitative
210

sandwich enzyme immunoassay technique as described.

Briefly, TGFβ soluble receptor

type II, which binds TGFβ1, was pre-coated onto a microplate. Standards and samples were
pipetted into the wells and any TGFβ1 present was bound by the immobilized receptor. After
washing away any unbound substances, an enzyme-linked polyclonal antibody specific for
TGFβ1 was added to the wells to sandwich the TGFβ1 immobilized during the first
incubation. Following a wash to remove any unbound antibody-enzyme reagent, I added a
substrate solution to the wells and color developed in proportion to the amount of TGFβ1
bound in the initial step. The color development was then stopped and the intensity of the
color measured. The intra-assay and inter-assay coefficients of reproducibility for these assays
are 6% and 9% respectively.

Serotonin ELISA
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I quantitatively measured serum serotonin levels by competitive enzyme-linked
immunosorbent assay (IBL, Hamburg), whereby there is competition between a biotinylated
and a non-biotinylated antigen for a fixed number of antibody binding sites. The amount of
biotinylated antigenic bound to the antibody is inversely proportional is the analyte
concentration of the sample. I performed this experiment under the supervision of Dr. Kidd.
All assay reagents were stored in the refrigerator and were allowed to reach room
temperature before starting the experiment. 20 μl of serum was pipetted into glass test
tubes. 100 μl of diluted Assay Buffer was added to each tube and vortex mixed. 25 μl of
Acylation Reagent was then added to each tube, vortex mixed, sealed with Parafilm, and
incubated for 15 minutes at 37° C. 4 ml of diluted Assay Buffer was added to each tube,
vortex mixed, and the precipitated proteins were removed by centrifugation (10 minutes at
1500 RPM). 50 μl aliquots of supernatant were then withdrawn immediately from each
sample. 15 μl of each standard, acylated control serum, and acylated patient samples were
pipetted into the appropriate wells. 50 μl of serotonin biotin were pipetted into the wells.
50 μl of serotonin antiserum was then pipetted into the wells and the ELISA plate was
shaken carefully. The plate was sealed with an adhesive foil and incubated 18 hours
overnight at 4° C. Each well was washed three times with Wash Buffer. The plate was
inverted and tapped firmly on clean blotting paper to remove any remaining liquid. 150 μl
of enzyme conjugates were pipetted into each well. The plate was then sealed with a piece of
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foil and incubated for 120 minutes at room temperature on an orbital shaker (500 RPM).
Each well was washed three times with wash buffer, and 200 μl of PNPP Substrate Solution
was then pipetted into each well. The plate was incubated at room temperature for 60
minutes on an orbital shaker (500 RPM). The substrate reaction was stopped by adding 50
μl of PNPP stop solution into all wells, and the contents were briefly mixed by gently shaking
the plate. The plate was immediately read with a microtiter reader at an optical density of
405 nm and the data analyzed with the assistance of Dr. Kidd using a cubic spline
function.
The results were calculated by subtracting the optical density of the substrate blank
from the optical densities of all standards in samples. The sample preparation leads to a 207fold dilution, and thus the values read from the standard curve were corrected by a
multiplying each value by 207 to give the serotonin concentration in ng/ml. The intra- and
interassay CVs were 7.2 and 10.5%, respectively.

Chromogranin A ELISA
I measured the serum CgA levels using a commercially available CgA ELISA kit
(Dako A/S, Denmark). The kit utilizes an immunoenzymatic sandwich methodology. The kit
can be used for measuring chromogranin A in the range 10 to 500 U/L, and the normal value
is ≤17 U/L. The ELISA is a simplified double antibody sandwich assay where the sample and
the conjugate were incubated simultaneously in antibody-coated wells, with results obtained
in 2 ½ hours. The total imprecision of the assay is less than 9% over the entire measurable
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range . The coefficient of variation ranged from 10.2% (intra-assay) to 12.4% (interassay).

SPECIFIC AIM #4: Determine if the identification of specific
fibrotic mediators would be helpful in screening candidate
fibrosis-associated genes and proteins in small bowel
carcinoid tumors.
GeneChip® DNA Microarray Studies
A variety of serum markers have been proposed to detect and predict fibrotic disease,
particularly hepatic fibrosis (most commonly in the context of hepatitis C infection) because
of their proposed ability to identify patients with increased or progressive collagen
212

synthesis . The use of serum markers as direct biochemical markers of fibrosis has been
evaluated in several studies. Among the more commonly investigated serum markers are
213

alpha-2-macroglobulin ,

hyaluronic

214,215

acid

(HA)

216

,

YKL-40,

gamma-glutamyl
217,218

transpeptidase (GGT) , procollagen type III N-terminal peptide (PIIINP)
219,220

metalloproteinases (MMP-1, MMP-2, MMP-9)

, and matrix

. The prothrombin index and HA

221

appear to be the best predictive factors for cirrhosis , while serum YKL-40 may be related to
the degree of liver fibrosis, with the highest levels found in patients with severe or moderate
222

cirrhosis and lowest in those without fibrosis . The combination of two serum markers
reflecting fibrogenesis (PIIINP) and fibrolysis (MMP-1) may provide a useful tool for
220

®

evaluating liver fibrosis . Commercially available serum kits, such as FibroTest and
®

ActiTest , have been developed for comprehensive analysis of six serum markers
simultaneously, but it is clear that these kits may not accurately predict the presence or
223

absence of significant liver fibrosis . The relevance of any of these markers to small bowel
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carcinoid fibrosis has never been evaluated, and the clinical utility of these kits (which were
developed for hepatic disease, as they measure liver markers of tissue damage) in detecting
small bowel carcinoid fibrosis is not known. Because the biology of small bowel carcinoid
fibrosis is poorly understood, it would be clinically useful to identify fibrotic mediators
specific to this tissue and then determine the clinical utility of these organ-targeted candidate
fibrotic proteins rather than using a hepatic-based test of undetermined relevance.
The tissue databank was used to identify the gene expression patterns of fibrotic
small bowel carcinoid tumors using the established Affymetrix-based GeneChip® approach .
224

Three groups of tumors were examined - gastric carcinoid tumors and two groups of small
bowel carcinoid tumors (invasive, non-fibrotic tumors and fibrotic tumors) and one control
group (normal small bowel mucosa).
Two gene analysis approaches were used. In the first, whole tissue sections from
carcinoid tumors were used. This allowed for the identification of both tumor and
surrounding tissue genes, providing an overall idea of the gene expression within the fibrotic
environment. In the second approach, elutriation-enriched (>95%) carcinoid tumor cells
from the three different groups were examined. These cells were obtained from the same
material as that used for the whole tissue sections. The minimum number of samples in a
group required to give a representative statistical result is three. Histologically identified
tumor material was used to provide material for the whole tissue approach.
Small bowel carcinoid and gastric carcinoid tumor cells were isolated and enriched by
Dr. Kidd using a procedure that he had developed, which provides a novel method for
producing highly enriched cell populations. After I collected fresh tumor tissue in the
operating room, I placed part of the specimen in warm RPMI media and delivered it
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immediately to Dr. Kidd, who hand dissected the tumor and digested it in collagenase
(0.25mg/ml)/DNAse (100U/mL) solution for 60 min at 37°C under constant aeration. A
7

total of 1-2x10 tumor cells were obtained from each preparation. Cells were then loaded
onto an elutriator at 20ml/min for 3 min at 2,000 rpm, washed for 10 min at 25ml/min at
2,500 rpm, and the fraction of interest was separated by counterflow-elutriation using a flow
rate of 55ml/min at a centrifugation speed of 2,000 rpm. This fraction was then applied to a
step Nycodenz gradient and centrifuged at 1,100 rpm for 8 min. Tumor cells collect at the
6

interface of a density of 1.070g/L, and the final cell count was 1-2x10 cells. This provided
sufficient RNA (4μg) for both GeneChip® and Q RT-PCR analysis.

RNA isolation (performed by Dr. Kidd): Total RNA was extracted from tumor tissue or from
cells using the RNeasy kit for lipid tissue (Qiagen, Valencia, CA.) and the quality assessed by
the Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA.) to visually verify the absence
of genomic DNA contamination, integrity and ratio of 28S and 18S bands, and by a A260/A280
ratio which was at least 1.8.
®

GeneChip Technology: Dr. Kidd generated target cRNAs and hybridized to human HU133A
using a GeneChip® approach (Affymetrix, Santa Clara, CA). The intensity was equally scaled
for each chip (intensity = 500) and genes normalized using the RMA algorithm. Thereafter,
differences in gene expression in the different groups were examined using GeneSpring
software.
The Affymetrix U133 Plus 2.0 array consists of over 1,300,000 unique
oligonucleotide sequences, which represent over 47,000 transcripts. The hybridized arrays
were scanned using a GeneChip® scanner 3000 (Affymetrix Inc. CA) at the Affymetrix
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Resource facility at Yale University. Arrays were scaled to an average intensity of 500 and
analyzed independently using Microarray Suite (MAS) 5.0 software (Affymetrix, Santa
Clara, CA). The hybridization intensity data will be converted into presence/absence calls for
each gene, and changes in gene expression between experiments were detected by comparison
®

analysis. The data was further analyzed by Dr. Kidd using NetAffx (Affymetrix, Santa Clara,
®

CA) and Gene Spring (Silicon Genetics, Redwood City, CA.).
In the first set of experiments, tumors from gastric carcinoid patients were used as a
baseline for the comparison with the two groups of small bowel carcinoid tumors (invasive,
non-fibrotic tumors and fibrotic tumors). Each candidate gene was normalized to the
median/mean intensity of that gene in the gastric carcinoid tissue. Only those genes with a
minimum signal intensity of 200 and where the average fold change of the small bowel
carcinoid patients was at least 1.5 were further analyzed. The Student one sample t-test, with
a p-value cut off of 0.05, was performed by Dr. Kidd to determine if the average ratio of the
small bowel carcinoid tumors was significantly different from 1.0, which would be the value
of the gastric carcinoid samples after normalization. Benjamini and Hochberg false discovery
225

rate was used for multiple testing corrections . Fibrosis-associated genes were defined as
those significantly up-regulated in the fibrotic small bowel carcinoid group but not in either
the non-fibrotic small bowel carcinoid or non-fibrotic gastric carcinoid groups. In the second
set of experiments, fibrotic small bowel carcinoids were examined against the baseline of
normal small bowel mucosa. Only those genes identified to be over-expressed in both sets of
experiments were examined further.

*Summary statement of my specific role in the design and completion of this study:
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I recruited all of the patients who participated in our study at Dr. Modlin’s weekly
neuroendocrine tumor clinic, and I occasionally attended Dr. Murren’s oncology clinic to
recruit additional patients. I was in regular contact with Marianne Davies, Jan Napoletano,
and Marianne Gallipoli, all nurses at the oncology clinic, who notified me when new patients
presented to clinic with neuroendocrine tumors. I consented every new patient for the study,
performed the phlebotomy to obtain serum samples, and I centrifuged each sample after
collection and isolated the serum by myself as described, which I then stored in the lab
freezer. I also interviewed each patient at clinic to obtain their medical history and collected
further information by reviewing their charts retrospectively. I collaborated with Dr. Vitali
Khomitch in the Department of Pathology, and he informed me whenever surgical pathology
identified a carcinoid tumor in a specimen. If the patient was still in-house, Dr. Khomitch
notified me so that I could recruit the patient for our study and collect a serum sample.
For tissue procurement, I regularly checked the operating room schedule to ascertain
whether any cases were scheduled in which a tissue sample might become available, and
several of the general surgeons at YNHH notified me in advance when performing resection
of gastrointestinal tumors. When tissue was made available, I was present in the operating
room to collect the specimen, dissect the tissue of interest (e.g. tumor, adjacent normal
mucosa, etc.), and I then stored it immediately in the -80°C freezer and/or in warm RPMI
media, the latter of which I would deliver to Dr. Kidd, the director of our lab, for his cell
culture experiments. The comprehensive tissue analysis included specimens that had been
collected prior to my joining the lab, but I collected every sample that became available
throughout the course of this project. Because this study was conducted over the course of a
year, I was able to follow several of our patients closely over several months to determine the
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objectives detailed in part 6 of the “Results” chapter (“effects of medical or surgical
intervention on CTGF serum levels”). Among the patients who presented for surgical
resection of bowel tumors, I performed daily serial phlebotomies post-operatively in addition
to the pre-operative sample I collected.
The RNA isolation and RT-PCR experiments were performed exclusively by Dr.
Kidd, and the carcinoid tissue microarray (TMA) had been constructed by Drs. Kidd and
Camp prior to the start of this project. However, the tissue I collected over the course of the
study was used to construct a second TMA that paired carcinoid tumor tissue with adjacent
normal mucosa. Immunohistochemical staining and AQUA analysis using the microarray was
however performed jointly by Dr. Kidd and me. We did the staining experiments together
and prepared the multi-color staining images using Photoshop. We performed the AQUA
analysis in Dr. Camp’s lab at Yale using the protocol described. In addition, we contributed
equally to the data analysis by using Microsoft Excel for statistical analysis.
I performed all serum ELISA assays with the assistance of Dr. Kidd, and we used
commercially available kits for each protein as described. We used a microplate reader in a lab
on the first floor of the BML research building to analyze the wells, and the protein
concentrations were calculated according to the guidelines outlined in the protocol of each
ELISA kit described and computation analysis was facilitated by using Microsoft Excel. I
performed all statistical analysis of the ELISA data with Dr. Kidd’s guidance and used this
data to construct the bar graphs that were included in the experimental section.
The GeneChip® analysis was completed by the Affymetrix Resource facility at Yale,
and while the samples I collected were used in the analysis, the experiments (e.g. RNA
isolation) were performed by Dr. Kidd. We collaborated on the biostatistical analysis once the
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data from these experiments were made available and worked together to prepare the figures
illustrating the data in my thesis.
Of note, the data presented in the thesis, as well as several of the figures, have been
presented at several meetings over the past year, including a surgical research seminar at Yale
in April of 2004, Student Research Day in May 2004, and at poster sessions at the January
2004 ASCO meeting in San Francisco and at the May 2004 DDW conference in New
Orleans. My preliminary data were included in my October 2003 Ohse grant application,
and Dr. Kidd used some of the data we generated in his recent Ohse grant application as well.
Dr. Modlin used some of my collages as part of his Grand Rounds presentation in October
2004.
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RESULTS
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1. EVIDENCE FOR CTGF EXPRESSION IN SMALL BOWEL CARCINOID TUMORS
AND NORMAL SMALL BOWEL MUCOSA
a) CTGF expression in normal small bowel tissue:
Immunofluorescent localization of CTGF in normal small bowel mucosa (Figure 23) and
small bowel carcinoid tumors (Figure 24) was performed in paraffin sections. CTGF was
localized in the cytoplasm of cells. In the normal small bowel, CTGF-positive cells were
identified in the base of the crypts. A dual staining approach identified low numbers of
double-stained CTGF and CgA- (15±5%) or serotonin-positive (30±12%) cells (Figure 23).

Figure 23A: Dual color staining of CgA (green – Alexa 488) and CTGF (red – Cy5) in normal small intestinal mucosa
(cross-section). Dual-stained cells are indicated by arrows (A). A minority of CgA cells (~15%) was also CTGF positive
(400x magnification).
Figure 23B: Dual color staining of CTGF (red – Cy5) and serotonin (green – Alexa 488) in normal small intestinal
mucosa (cross-section). Dual-stained cells (red + green = yellow) are indicated by arrows (B). A minority of serotoninproducing cells (~30%) was also CTGF positive (600x magnification).

b) CTGF expression in small bowel carcinoid tumors:
In the small bowel carcinoid tumors, co-staining with anti-CgA (Figure 24A) or antiserotonin (Figure 24B) antibodies demonstrated a significant co-localization with CTGF and
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Figure 24A: Triple color staining of nuclei (blue – DAPI), CgA (green – Alexa 488) and CTGF (red – Cy5) in
a carcinoid tumor from the carcinoid tissue microarray. Staining for both CgA and CTGF was cytoplasmic. Dualstained (CgA + CTGF) cells are yellow. A majority of CgA cells (~80%) were also CTGF positive. (400x
magnification).
Figure 24B: Triple color staining of nuclei (blue – DAPI), serotonin (green – Alexa 488) and CTGF (red –
Cy5) in a carcinoid tumor from the carcinoid tissue microarray. Staining for both Serotonin and CTGF was
cytoplasmic. Dual-stained (Serotonin + CTGF) cells are yellow. A majority of the serotonin cells (~95%) were also
CTGF positive. (600x magnification).

either antibody (80±12% and 93±6% respectively) in tumor mucosa. These results
demonstrate that the majority of small bowel carcinoid tumor cells express CTGF (90%).

c) The CTGF secretory pathway in small bowel tumor cells:
Serial sections from carcinoid tumors were stained for nuclei and CTGF or the
specific Golgi-marker protein 58K. Staining demonstrated overlapping distribution of CTGF
and 58K, indicating that CTGF was synthesized via the constitutive pathway in small bowel
carcinoid tumor cells (Figure 25). This is consistent with the findings in dermal fibroblasts
226

and activated hepatic stellate cells . These results demonstrate that CTGF is actively
synthesized in the Golgi network in the tumor cells.
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Figure 25: Dual color staining of nuclei (blue – DAPI) and either CTGF
(red – Cy5) [left] or anti-58K (golgi staining) (red – Cy5) [right] in 2
serial sections from the same small bowel carcinoid tumor. These show
overlapping distribution of CTGF and the Golgi apparatus demonstrating
that CTGF is secreted through the constitutive pathway in the tumor.

2. QUANTITATIVE RT-PCR ANALYSIS DEMONSTRATES CTGF AND TGFβ1
EXPRESSION IN SMALL BOWEL AND GASTRIC CARCINOID TUMORS
Quantitative RT-PCR (Q RT-PCR) analysis was undertaken using Assays on
Demand (Applied Biosystems) on the RNA isolated from small bowel EC carcinoids (n=5);
gastric ECL cell tumors (n=5); normal small bowel samples (n=4) and normal gastric
mucosa (n=5) to quantitatively measure the levels of CTGF and TGFβ1 mRNA expression in
these two different tumor types. Small bowel tumors develop fibrosis while gastric carcinoids
do not.

a) Small bowel versus gastric carcinoids:
Message for both CTGF and TGFβ1 were significantly elevated in the 5 small bowel
carcinoid tumor samples (p<0.05 vs. normal mucosa) (Figure 26). In contrast, although
TGFβ1 message was not different (+1.13–fold) in gastric carcinoid tumor samples, message
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levels of CTGF were significantly
decreased

(-1.3–fold;

p<0.01)

compared to small bowel carcinoid
tumors (Figure 26). These results
demonstrate that both gastric and small
bowel carcinoids express mRNA for
TGFβ1, and that CTGF message is
over-expressed only in small bowel
carcinoid tumors.

b) Correlation between CTGF and
TGFβ1:

Figure 26: Message levels of both CTGF and TGFβ1
determined by Q RT-PCR. Levels were corrected against
expression of the housekeeping gene, GAPDH, compared to
similarly corrected gene levels in normal mucosa, and
represented as fold increase over normal (1.0). CTGF and

TGFβ1 were significantly over-expressed (~2.5-fold) in
small bowel carcinoid tumor samples compared to normal

There was a good correlation

mucosa (*p<0.05) but not the gastric carcinoids. Gastric
carcinoids had significantly decreased CTGF compared to

(R =0.95) between CTGF and TGFβ1

small bowel carcinoid tumors (**p<0.01). Mean±SEM,

2

n=4-5.

message levels (Figure 27) in the small
bowel carcinoid samples demonstrating that transcription of these growth factors was tightly
associated in this tumor tissue. These results thus demonstrate that CTGF and TGFβ1
message levels are strongly correlated.

3. A FUNCTIONAL TGFβ1/CTGF AXIS SPECIFICALLY OCCURS IN SMALL
BOWEL TUMORS ASSOCIATED WITH CLINICALLY DOCUMENTED
PERITONEAL FIBROSIS
The immunohistochemical expression of the TGFβ1 pathway in gastric carcinoids and in
small bowel carcinoid tumors from patients with or without clinically relevant retroperitoneal
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fibrosis was examined (Figure 28).

a) TGF β1: Initially, the expression of
TGFβ1—the upstream effector of CTGF
synthesis—was examined in order to assess
whether expression levels of this growth
factor could differentiate patients with or
without fibrosis. We noted that patients
with gastric carcinoids had high TGFβ1
scores (AQUA score: 93.7±5). Although
TGFβ1 expression levels were elevated in

Figure 27: Correlation analysis of Q RT-PCR results in
small bowel EC carcinoids. There was a good correlation

patients

between CTGF and TGFβ1 message levels in tumor
samples (R2=0.95, p<0.006, n=5).

with

fibrosis

(AQUA

score:

90.6±4.4) compared to the patients with no
evidence of fibrotic disease (AQUA score: 82.7±4) this was not statistically different
(p=0.12).

b) TGFβRII: TGFβ1 mediates its effects by binding and activating the membrane
receptor – TGFβRII. We investigated staining of this receptor to test whether this was altered
during fibrosis.
Significantly higher scores for TGFβRII were noted in patients with fibrosis (AQUA
Score: 36.2±4.5) compared to patients without fibrosis (AQUA Score: 22.3±2.5; p<0.01).
Gastric carcinoid patients had an intermediate score (29.3±2.3). This indicates that TGFβRII
may be down-regulated in small bowel carcinoid tumor patients that do not generate fibrosis.
Alternatively, the receptor may be over-expressed on tumor cells.
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Figure 28: AQUA scores for TGFβ1 pathway protein expression in patients with small bowel carcinoids
(with or without clinically documented fibrosis) or gastric carcinoids on the tissue microarray. Levels of
TGFβ1 were not different. TGFβ1RII levels were increased in patients with fibrosis compared to nonfibrotic patients (p<0.01). Receptor levels were also elevated in gastric carcinoid patients but this was not
significant. Nuclear staining of phosphorylated SMAD2 was elevated (p<0.03) in fibrotic compared to
non-fibrotic patients. Levels were also significantly elevated in gastric carcinoid tumors (p<0.05)
compared to non-fibrotic patients. CTGF, the downstream target of the TGFβ pathway was significantly
increased only in patients with fibrosis. (*p<0.05, **p<0.01). Mean±SEM, n=15-22.
Mean immunostaining levels for non-carcinoid tissue (liver, bowel tissue) were:
TGFβ1

TGFβRII

pSMAD

CTGF

Liver

60±3

12±2

85±7

61±5

Bowel

52±5

9±2

74±6

70±12

c) Phosphorylated SMAD2: Activation of TGFβRII following TGFβ1 binding results in
phosphorylation of the SMAD intracellular signaling pathway. Specifically, SMAD2 is
phosphorylated and translocates to the nucleus where it is involved in mediating
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transcription.
High AQUA scores of nuclear pSMAD2 were noted in gastric carcinoids (160±12),
indicating that these cells are TGFβ1 responsive. Higher pSMAD2 AQUA scores were noted
in patients with fibrosis (150±9) compared to those without fibrosis (116±11; p<0.05).
This suggests that both gastric and small bowel carcinoid tumors (associated with fibrosis)
demonstrate a functional response to TGFβ1.

d) CTGF: CTGF is the downstream target of TGFβ1 signaling. TGFβ1 specifically
initiates transcription of the CTGF gene in cells that are responsive to this pathway. Higher
levels of CTGF staining (AQUA score: 92.5±8.2; p=0.017) were identified in small bowel
carcinoid patients with fibrosis compared to the patients (AQUA score: 72.7±3.2) with no
clinical evidence of fibrotic disease. In addition, despite a functional TGFβ1 pathway, CTGF
was not highly expressed in the gastric carcinoids.

4. SERUM LEVELS OF CTGF AND TGFβ1 ARE ELEVATED IN PATIENTS WITH
SMALL BOWEL AND GASTRIC CARCINOID TUMORS
Having established that CTGF message and protein levels were elevated in patients
with small bowel carcinoids, we next evaluated whether serum levels of CTGF were
measurable and if they correlated with tissue levels. In addition, we examined serum levels of
TGFβ1, and the two carcinoid secretory products Chromogranin A and serotonin. The latter
were included because these are carcinoid tumor markers and serotonin has been proposed as
90

a potential marker of cardiac fibrosis .

a)

CTGF and TGFβ1 in normal subjects and in carcinoid patients: Serum levels of
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CTGF ranged from 7.2–60 ng/mL and
TGFβ1 from 5.6–88 ng/mL. Significantly
higher serum CTGF levels were found in
patients with small bowel carcinoids
(24.2±1.8) than in patients with gastric
carcinoids (11.8±0.7, p<0.03) and normal
subjects (10±0.2, p<0.02) (Figure 29).
Serum levels of TGFβ1 were also elevated
in patients with small bowel carcinoids
(35.4±1.4) compared to gastric carcinoid
patients (22.5±1.2, p<0.02) and normal
subjects (23.9±5, p<0.04). Comparing

Figure 29: Serum levels of CTGF and TGFβ1 in normal
subjects, patients with gastric carcinoids and patients with
small bowel carcinoids. Levels (ng/mL) of CTGF were
significantly elevated (>2-fold) in patients with small bowel
carcinoids compared to normal subjects or patients with
gastric carcinoids. Levels (ng/mL) of TGFβ1 were elevated
~1.5-fold in small bowel carcinoid patients compared to
gastric carcinoids and versus normal subjects. *p<0.02 vs.

serum CTGF levels with tissue levels
(AQUA

scores)

identified

a

normal subjects and gastric carcinoids. Mean±SEM. n=1012.

strong
2

correlation between these two measurements (R =0.91, p<0.005, n=9).
b) Chromogranin A and serotonin in normal subjects and in carcinoid patients: Serum
levels of Chromogranin A ranged from 2–976 U/L and serotonin from 9–1247 ng/ml.
Gastric (89±16, p<0.05) and small bowel carcinoid (298±111, p<0.01) patients had
significantly elevated Chromogranin A levels compared to normal subjects (14±7) (Figure
30). Small bowel carcinoid patients had elevated serotonin levels (250±52, p<0.01)
compared to gastric carcinoid patients and normal subjects.
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These two markers
are important for several
reasons:

they

carcinoid

distinguish

tumors;

serum

serotonin is a marker for EC
cells; and serum levels of
serotonin have been shown
to be related to cardiac
fibrosis.
Collectively,
results

these

demonstrate

that

serum levels of CTGF and
TGFβ1 are elevated in small
bowel

carcinoid

compared

to

patients

those

Figure 30: Serum levels of Chromogranin A and serotonin in normal
subjects, patients with gastric carcinoids and patients with small bowel
carcinoids. Levels (U/mL) of Chromogranin A were significantly elevated in
patients with gastric and small bowel carcinoids compared to normal subjects.
Levels (ng/mL) of serotonin were elevated in small bowel carcinoid patients
compared to gastric carcinoids and versus normal subjects. *p<0.05 vs.
normals, **p<0.01 vs. normals and gastric carcinoids. Mean±SEM. n=10-

with

gastric carcinoids, and that serum and tissue levels of CTGF are highly correlated.
Furthermore, small bowel carcinoid tumors secrete Chromogranin A and serotonin at
detectable levels as expected.

5. SENSITIVITY AND SPECIFICITY OF CTGF SERUM LEVELS IN PATIENTS
WITH SMALL BOWEL CARCINOID TUMORS
Calculations of sensitivity and specificity of CTGF were undertaken on CTGF levels
from 30 patients (small bowel carcinoids [n=10], gastric carcinoids [10], normal subjects
[10]). CTGF levels were set at 10 ng/ml (upper level of normal) and 15ng/ml (upper level
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identified in gastric carcinoid patients). The sensitivity and specificity for detecting patients
with small bowel carcinoids versus gastric carcinoids or normal subjects is shown in Table 1.
Table 1. Sensitivity and specificity of CTGF as a biomarker
Small bowel vs. Normal

Gastric vs. Normal

Small bowel vs. Gastric

CTGF cut-off
level

10ng/ml

15ng/ml

10ng/ml

15ng/ml

10ng/ml

15ng/ml

Sensitivity (%)

100

70

70

0

100

70

Specificity (%)

100

100

100

100

30

100

Three of 10 small bowel carcinoid patients had symptomatology consistent with
disseminated disease; the serum CTGF levels in these patients were elevated and ranged from
37-60 ng/ml. These results demonstrate that serum CTGF levels specifically identify patients
with small bowel carcinoids with a sensitivity that is dependent on patient symptomatology.

6. EFFECTS OF MEDICAL OR SURGICAL INTERVENTION ON CTGF SERUM
LEVELS IN PATIENTS WITH SMALL BOWEL CARCINOID TUMORS
Having established that CTGF was secreted and detectable in the serum of patients
with small bowel carcinoid tumors, the next objective was to evaluate how consistent the
levels of this growth factor were. I examined 6 patients at 3-month intervals to assess the
inter-patient variability. I next examined the effects of medical intervention (e.g. octreotide
therapy) or surgical intervention on serum levels of this growth factor.

a)

Inter-patient variability: Six patients with gastric (n=3) or small bowel (n=3)

carcinoid tumors were examined 3 months apart. Initial serum levels ranged from 10-60
ng/ml and at 3 months ranged between 10-58 ng/ml. The mean serum level at entrance was
21.8±7.8 and at 3 months was 20±7.8. A 2-tailed paired t-test identified no difference
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between the two sample sets (p=0.40). The
coefficient of reproducibility of the two
samples was 95.5% (Figure 31).

b) Medical intervention: Four patients
who

were

treated

with

long-acting

somatostatin analogs were examined before
and 24 hours after somatostatin analog
injection. No significant differences were

Figure 31: Temporal relationship of serum CTGF
levels in gastric and small bowel carcinoid patients.

noted (28±9 vs. 31±12; p=0.4).

There was a good temporal correlation for this growth
factor (Coefficient of reproducibility >95%, n=6).

c)

Surgical intervention: Serum levels

of CTGF were examined in four carcinoid patients who underwent surgery for removal of
their tumors. Serum was collected pre-operatively and 24 hours post-operatively. No
appreciable differences were noted in CTGF
levels post-operatively (15.2±2 vs. 12±1.2;

p=0.31) (Figure 32). All four patients had
extensive mesenteric tumor and hepatic
metastases. These results demonstrate that
CTGF levels remain elevated because hepatic
metastases still produce CTGF (Figure 33).
Patients with extensive disease would be
predicted to develop fibrosis, an outcome

Figure 32: CTGF serum levels in four carcinoid patients

consistent with the hypothesis.

before (pre-operatively) and one-day post-operatively.
CTGF levels did not appreciably change (n=4).
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Figure 33: Triple color staining of nuclei (blue – DAPI), cytokeratin (green – Alexa 488) and CTGF (red –
Cy5) in liver metastases (LM) and lymph node (LN) material. Extensive CTGF staining is present in all tumor
cells (400x magnification). AQUA scores for CTGF in liver metastases (95±12) and lymph node material
(87±13) were similar to primary tumor levels (92±9) and significantly elevated (p<0.01) versus normal mucosa
(62±5).

These results suggest that serum levels of CTGF remain stable over a 3-month
period; surgical intervention did not significantly alter serum CTGF levels after 24 hours;
and liver and lymph node metastases express CTGF.

7. GENECHIP® ANALYSIS OF GASTRIC AND SMALL BOWEL CARCINOIDS
Material from 29 tissue blocks (n=23 patients) was examined using Affymetrix
GeneChip® analysis. Total RNA was isolated from each sample using the RNeasy kit
(Qiagen). Target cRNAs were generated and hybridized to human HU133A GeneChip®
(Affymetrix, Santa Clara, CA). The intensity was equally scaled for each chip (intensity =
500) and genes normalized using the RMA algorithm. Thereafter, differences in gene
expression in the different groups were examined using GeneSpring® software.
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a)

Cluster analysis of gene expression: Global gene expression patterns clearly distinguished

between the two different organs (stomach and small bowel) as well as the different tumor
types (gastric and invasive small bowel carcinoid) (Figure 34).

b) GeneSpring analysis: GeneSpring analysis identified 1294 gene significantly altered in
the non-fibrotic gastric carcinoid tumors and 1709 genes in the invasive small bowel
carcinoids compared to normal gastric and small bowel mucosa respectively. Direct
comparison of gene expression in each tumor group identified 1294 genes that significantly
altered between them; 375 genes were up-regulated in small bowel carcinoids and 919
down-regulated.

Figure 34: Hierarchical clustering of 29 Affymetrix chips including normal stomach (NS; n=8), gastric
carcinoid (GC; n=8), normal small bowel (NSB; n=6) and small bowel carcinoid tumors (SBC; n=7).
Expression levels 0-5.0 are indicated on the right.
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c)

Fibrotic genes specifically expressed in small bowel carcinoids compared to gastric carcinoids:

The gene profiles of these two tumor types were next examined to identify whether fibrosisassociated genes were selectively expressed in small bowel carcinoids. Specifically, the genes
identified to be useful markers in liver and pancreatic fibrosis were examined. These genes
included hyaline genes, YKL-40, gamma-glutamyl transpeptidase (GGT), alpha-2macroglobulin, procollagen type III N-terminal peptide (PIII-NP), and the matrix
metalloproteinases (MMP-1, MMP-2, MMP-9)

213-220

. Genes that were significantly altered in

invasive small carcinoids were tabulated (Table 2).

Table 2. Potentially clinically relevant fibrotic associated genes in invasive small bowel carcinoids.
Small bowel carcinoid tumor

Small bowel carcinoid tumor

versus

versus

Gastric carcinoid

Normal small bowel

Gene

Fold-change

p-value

Gene

Fold-change

p-value

apolipoprotein A-I

+13.7

0.0054

apolipoprotein A-I

NS

NS

apolipoprotein A-I

+12.05

0.011

apolipoprotein A-I

NS

NS

α-2-macroglobulin

+1.97

0.034

α-2-macroglobulin

+2.32

0.005

procollagen

+1.52

0.011

procollagen

NS

NS

(type III) N-

(type III) N-

endopeptidase

endopeptidase

Although apolipoprotein A-I and procollagen N-endopeptidase were over-expressed
in small bowel carcinoids, they were not different when examined against normal small bowel
mucosa.
These results indicate that mRNA for alpha-2 macroglobulin, whose protein product
has been demonstrated to have a sensitivity and specificity of 75% and 67%, respectively, for
227

predicting significant fibrosis in patients with liver disease , is upregulated in invasive small
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bowel carcinoids. Alpha-2 macroglobulin shares a common receptor with CTGF. An
examination of CTGF demonstrated that this gene was variably expressed in small bowel
carcinoid samples (+0.4→+3.5-fold). This supports the hypothesis that CTGF is a
selectively expressed gene in small bowel carcinoids.
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DISCUSSION

The consequences of peritoneal and cardiac fibrosis are major clinical issues
associated with carcinoid tumors of the small bowel. Because so little is understood of the
mechanistic basis of fibrosis, there is no method to detect it before it causes either bowel
obstruction or cardiac valve dysfunction, nor is there a treatment to control carcinoid-related
fibrosis. As opposed to healing tissue, carcinoid tumors provide a unique, homogenous, welldefined cell system to study the evolution of fibrosis.
An interdisciplinary approach using clinical material, DNA microarrays, protein
expression profiling and tissue microarray analysis has allowed us to identify CTGF as the
most likely mediator associated with small bowel carcinoid fibrosis. The proteomic and tissue
microarray analysis in these studies demonstrated that at a tissue level small bowel carcinoids,
like gastric carcinoids, have an intact, active TGFβ1 signaling pathway, but only the small
bowel carcinoids synthesize and secrete CTGF at clinically significant elevated levels
compared to both the normal small bowel mucosa and the non-fibrotic ECL cell carcinoid
tumors. Since only the EC carcinoids are associated with fibrosis, our results support the role
of CTGF as a candidate regulator of small bowel carcinoid fibrosis. Serum levels of both
CTGF and TGFβ1 were significantly increased in ileal carcinoid tumors compared to other
GI neuroendocrine tumors, and the results demonstrated strong correlations between serum
CTGF and TGFβ1 and between CTGF and CgA, indicating firstly that CTGF and TGFβ1 are
co-secreted, and that CTGF may be not only a marker for fibrosis but in addition a marker
specific to ileal EC carcinoid tumors.
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Our data further demonstrates that small bowel carcinoids have >2-fold levels of
CTGF compared to gastric carcinoids, and patients with symptomatology consistent with
metastatic disease have >5-fold levels of CTGF. Elevated levels of CTGF (>14ng/ml) are
11

highly correlated with fibrosis and identify scleroderma patients , and 70% of midgut
carcinoid patients have CTGF levels >15ng/ml. Up to 50% of these patients will develop
local or distant (cardiac) fibrosis. Furthermore, we were able to demonstrate that serum
CTGF levels in patients with carcinoids are stable over a 3-month period and therefore
monitoring this protein has predictive utility; that long-acting somatostatin analogue therapy
(octreotide) does not significantly alter serum CTGF levels; and that surgery only causes a
transient increase in CTGF that returns to pre-operative baseline within 24 hours. These
results suggest that CTGF can identify small bowel carcinoid patients and potentially has
sufficient discrimination for the detection of fibrosis.
Additionally, we were able to identify, using the GeneChip® studies in normal gastric
and small bowel mucosa and gastric and small bowel carcinoids (n=29 samples), that the
candidate fibrotic factor, alpha-2-macroglobulin (which shares a common receptor with
CTGF) is over-expressed in invasive midgut carcinoids. This has been shown to be relevant
in hepatic stellate cell-driven fibrosis and may provide an alternative factor to examine in
small bowel carcinoid fibrosis.
A molecular understanding of carcinoid development and progression is an important
step toward the identification of biomarkers with increased specificity for fibrosis and for the
development of novel fibrosis-specific therapeutic targets. While TGFβ has long been a
therapeutic target for the treatment of fibrotic disorders, it also has normal functions in the
body that make chronic administration of any inhibitor that indiscriminately blocks TGFβ
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activity problematic due to unwanted side effects. Selectively inhibiting CTGF activity in the
body would be a better strategy, as its unregulated over-expression is what leads to
persistent, chronic fibrosis. The use of antibodies that inhibit CTGF has the potential to
arrest the progression of fibrosis and provide an opportunity to preempt the local and
systemic complications commonly associated with small bowel carcinoid tumors. It is also
probable that such an approach in these tumors will be applicable to other fibrotic disease
processes as well.
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